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Abstract. Ginseng is one of the main representatives of 
traditional Chinese medicine and presents a wide range of 
pharmacological actions. Ginsenosides are the main class 
of active compounds found in ginseng. They demonstrate 
unique biological activity and medicinal value, namely anti-
tumour, anti-inflammatory and antioxidant properties, as 
well as anti-apoptotic properties. Increasing levels of stress 
in life are responsible for the increased incidence of nervous 
system diseases. Neurological diseases create a huge burden 
on the lives and health of individuals. In recent years, studies 
have indicated that ginsenosides play a pronounced positive 
role in the prevention and treatment of neurological diseases. 
Nevertheless, research is still at an early stage of development, 
and the complex mechanisms of action involved remain largely 
unknown. This review aimed to shed light into what is currently 
known about the mechanisms of action of ginsenosides in rela-
tion to Alzheimer's disease. Scientific material and theoretical 
bases for the treatment of nervous system diseases with puri-
fied Panax ginseng extracts are also discussed.
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1. Introduction
Alzheimer's disease (AD), which is the most common form of 
dementia, is a neurodegenerative disease that was first described 
by the German psychiatrist, Alois Alzheimer in 1907 (1). 
Despite great progress being made in the understanding of the 
pathogenesis of AD, no cure has yet been found. Three main 
neuropathological signs characterize AD: The loss of neurons, 
amyloid plaques and neurofibrillary tangles (NFTs) (2). 
Amyloid plaques are predominantly composed of peptides, 
known as β-amyloid (Aβ), which are the main peptides to induce 
neuronal damage and apoptosis in patients with AD (3). NFTs 
are formed from the hyperphosphorylation of Tau protein (also 
known as τ protein) (4,5).
2. The history of ginseng as a drug
The ancient and rich experience of folk medicine in the countries 
of the Far East has paved the way for many valuable scientific 
medicines, and ginseng occupies a special place in this important 
group. The first information about this medicinal plant can be 
traced back into the distant past and is surrounded by an aura 
of legend and tradition. For dozens of centuries, ginseng has 
been the subject of worship for the peoples of the Far East and 
has played a significant role in the culture, commerce and even 
foreign policy of China and other East Asian states.
The first to discover the healing properties of ginseng, 
according to legend, is Lao Tzu (6th century BC), the founder 
of a religious and philosophical school in China. Ginseng has 
been known of for at least 4,000 years. The first mentions of 
it are found in the most ancient writings on medicinal plants, 
‘Shen-nun’ and ‘Shen-Lun-ben-cao’, which date back to the 
20th century BC. Numerous recommendations for the treat-
ment of various diseases with ginseng are available in the new 
edition of the ‘E-lin’ medicine collection, compiled in China by 
Shi Bao-yuan in 2-1 BC. Ginseng is also described in several 
ancient Chinese sources from the 3rd century onwards (6,7).
Carl von Linné was the first to provide a systematic description 
of the genus and named it Panax L. (Linné, 1742; https://books. 
google.ru/books?id=30Y-AAAAcAAJ&dq=Genera+Plantarum 
&printsec=frontcover&source=bl&ots=kI_cpWWP3x&sig=DbalIy 
FFHckeYxWqW-TegJC9iHs&hl=en&ei=07odS9_iE5HKsQPzotSECg 
&sa=X&oi=book_result&ct=result&redir_esc=y#v=onepage& 
q&f=false). This title [from the Greek words ‘pan’ (meaning all) 
and ‘asos’ (meaning medicine)] reflects the idea of the all‑ 
healing properties of ginseng. Russian scientists have become 
increasingly interested in ginseng since the 19th century. The 
work of Kamensky (he studied Far Eastern ginseng for the first 
time) was followed by that of the Russian botanist and explorer, 
Carl Anton von Meyer (1841-1842) which deepened the 
knowledge of the taxonomy of the genus Panax and established 
the boundaries of the species, which are still accepted to this 
day. He described 5 types of ginseng and assigned the name of 
Panax Ginseng C.A.Meyer to true ginseng, and this name still 
holds to the present day (8,9; and Refs therein).
Reliable information on ginseng was provided by the 
writings of Far Eastern Russian researchers [Arsenyev (10), 
Przhevalsky (11), Maak (12), Maksimovich (13) and 
Komarov (14)]. In 1868, Y.K. Trapp (https://ru.wikipedia.
org/wiki/Трапп,_Юлий_Карлович) included ginseng in his 
pharmacognosy guide. 
Relevant studies on the biology and culture of ginseng 
[Shishkin (15), Gutnikova (16,17), Vysotsky (18), Bayanova (19) 
and Kurentsova (20)], have been carried out in the Far East 
of the former USSR since 1930. Several pharmacological 
[Zakutinsky (21), Burkat and Saksonov (22) and Kiselev (23)] 
and clinical works [Shapiro (24), Kuzminskaya (25) and 
Buturlin (26)] have been published since then. The Far Eastern 
academician scientists, Elyakov (founder of the Institute of the 
Far Eastern Branch of the Russian Academy of Sciences) and 
Brekhman provided significant contributions to the develop-
ment of the science of Far Eastern medicinal plants, including 
ginseng (7,27).
The main active ingredients in ginseng are triterpene 
glycosides. These are ginsenosides, although they were more 
commonly known as panaxosides in the past. This was due 
to the fact that the pioneers of the study of ginseng saponins 
were domestic organic chemists under the guidance of the 
Academician of the Far East Branch of the Russian Academy 
of Sciences, G.B. Elyakov, who was the first to isolate 6 ginseng 
glycosides. The properties of an aglycone (a part of a glycoside 
that lacks a carbohydrate radical), led this group of scientists 
to term the glycosides of the protopanaxatriol group panaxo-
sides, A, B and C, and the glycosides of the protopanaxadiol 
group panaxosides, D, E and F. Over time, other members of 
these groups were isolated; however, as there was no space left 
between C and D, the new opening compounds were termed 
ginsenosides and numbers that correspond to their mobility on 
chromatograms were assigned to them (7,28,29).
3. The chemical composition of Panax Ginseng C.A. Meyer
Saponins, which belong to the tetracyclic triterpene group, 
are among the biologically active substances (BAS) that are 
found in ginseng. Ginseng saponins are said to belong to the 
triterpenoid group of steroid origin (29).
Triterpene glycosides (ginsenosides) are considered the 
main active ingredients of ginseng, which were previously 
often termed panaxosides. The pioneers of the study of 
ginseng saponins are a group of Russian scientists led by the 
Academician Far Eastern Branch of the Russian Academy 
of Sciences, G.B. Elyakov. They were the first to isolate 
6 glycosides of Panax ginseng in the 1960s (6,7). They termed 
the glycosides of the protopanaxatriol group, panaxosides A, 
MOLECULAR MEDICINE REPORTS  19:  2975-2998,  2019 2977
B, and C, based on the properties of the aglycone, and the 
glycosides of the protopanaxadiol group, the panaxosides D, 
E and F. Over time, other members of these groups were 
identified; however, since there was no space between C and D, 
newly discovered compounds began to be termed ginsenosides 
and assigned numbers to them corresponding to their mobility 
shown on the chromatograms.
When clarifying the structure of an aglycone that ginseng 
glycosides, it was found to contain 3-6 monosaccharide resi-
dues (glucose, rhamnose, arabinose and xylose). Almost all 
glycosides have two carbohydrate chains bound to aglycone 
through typical glycosidic bonds.
The systematization of the literature data on the chemical 
composition of ginseng has led to data that are presented 
in Table I.
It is now established that the composition of the dry root is 
approximately as follows: Ginsenosides, 1-6%; carbohydrates 
(polysaccharides, trisaccharides, disaccharides, monosaccha-
rides, cellulose, pectins), 60-70%; nitrogen-containing compounds 
(amino acids, etc.), 12-16%; fat soluble components, 2%; vita-
mins, 0.05%; mineral substances 4-5% and moisture, 9-11% (28).
4. Ginsenosides and the acetylcholine level
Acetylcholine (ACh) is the main neurotransmitter in the 
parasympathetic nervous system and is rapidly destroyed by 
specific enzymes, known as cholinesterase, in the body. In addition 
to acetylcholinesterase (AChE), butyrylcholinesterase (BChE) 
can also destroy Ach (30). AChE and BChE play a significant role 
in AD. The inhibition of AChE and BChE provides additional 
benefits in the treatment of asthma. The cholinergic hypothesis, 
according to which the disease is caused by the reduced 
synthesis of ACh, was the first hypothesis to be proposed as 
the cause of AD. Indeed, the concentration of ACh in the brain 
during the first stages of AD is significantly below normal, and 
a decrease in the activity of cholinergic neurons is observed 
as a result (31). AChE inhibition-based therapy, which aims to 
increase the amount of Ach, is a method with which to alleviate 
AD in the initial and moderate stages (32). There are currently 
some doubts as to the cholinergic theory, as drugs that increase 
the level of ACh have a low efficiency. However, impelling 
methods of maintenance therapy have been created on this 
basis (33). Donepezil, galantamine and rivastigmine are three 
AChE inhibitors that form the basis of maintenance therapy for 
individuals with asthma. The continuous use of these drugs can 
lead to side-effects, such as headaches, constipation, dizziness, 
nausea, vomiting and a loss of appetite, which severely affect the 
quality of life of patients (34).
AD presents with both increased AChE activation and the 
inhibition of choline acetyltransferase (ChAT), which is the 
enzyme responsible for ACh biosynthesis (35).
Molecular docking and in vitro analyses have demonstrated 
that some of the ginsenosides that are obtained from ginseng 
root are AChE and BChE inhibitors. Ginsenosides Rb1, Rb2, 
Rc, Re, Rg1 and Rg3 have a significant inhibitory effect against 
AChE and BChE. The ginsenoside Re appears to provide the 
optimal AChE inhibitory activity from a series of ginsen-
osides (36).
The order of the inhibitory potential was as follows: Re>Rg3> 
Rg1>Rb1>Rb2>Rc for AChE, and Rg3>Rg1>Rb2>Rb1>Re>Rc 
for BChE. Ginsenoside Rc exhibited a weak inhibitory activity 
against AChE, while ginsenosides Rc and Re did so against 
BChE, compared with the positive controls (36).
Five new ginsenosides that are derivatives of ursolic acid 
have been isolated from Panax japonicus (37). All five were 
identified as AChE inhibitors in an evaluation of AChE activity 
in a PC12 cell model (rat adrenal pheochromocytoma) that was 
treated with Aβ25-35. However, it was found that their inhibitory 
potential was lower than that of donepezilum.
An extract from Panax quinquefolius (Cereboost™) 
was shown to exhibit AChE inhibitory activity in a mouse 
model of AD (male ICR mouse that received Aβ1-42 
intracerebroventricular) (38). Cereboost™ increased the level 
of ACh in the brain by inhibiting AChE and reduced the level 
of Aβ1-42, while it improved the cognitive abilities of mice. 
In vitro, Cereboost™ increased ChAT expression and reduced 
the cytotoxicity of Aβ1-42. Identical results have been observed 
in other studies on mouse models of AD (ICR mice injected 
with scopolamine) (38). Ginsenoside Rg1 has been proven to 
be a more potent AChE inhibitor than Rb1 (40). Furthermore, 
ginsenoside Rg5 has been observed to dose-dependently inhibit 
AChE and activate ChAT in another model of AD (Wistar rats, 
which were injected with intracerebroventricular streptozocin). 
It also increased the ability of rats to learn and memorize the 
Morris water maze (MWM) (41).
It was also previously shown that an extract from a 
4-year-old Panax ginseng C.A. Meyer root inhibited the 
neurotoxicity of Aβ. Choi et al examined the effect of dried 
white ginseng extract (WGE) on neuronal cell damage 
and memory impairment in mice injected with intrahip-
pocampal AβO (10 µM). Mice were treated with WGE (100 
and 500 mg/kg/day, p.o.) for 12 days after surgery. WGE 
improved memory impairment by inhibiting hippocampal 
cell death induced by AβO. In addition, the AβO-injected 
mice treated with WGE exhibited a restoration of reduced 
synaptophysin and ChAT intensity, and lower levels of ionized 
calcium-binding adaptor molecule 1 in the hippocampus 
compared with those of the vehicle-treated controls. These 
results suggest that WGE reverses memory impairment in 
AD by attenuating neuronal damage and neuroinflammation 
in the hippocampus of mice injected with AβO (42).
Some studies have shown that ginsenosides exert a 
neuroprotective effect by acting on neurotransmitters in 
AD. For example, ginsenosides can increase the levels of 
γ-aminobutyric acid, Ach and dopamine, and reduce the levels 
of glutamate and aspartic acid in the hippocampus and cere-
bral cortex. In addition, ginsenosides can increase the level of 
glycine and serotonin in the blood (43). Apparently, ginseng 
contains substances that can increase the level of Ach in the 
brain of people with AD. Ginseng extracts can thus be used as 
palliative treatment in the early stages of AD.
5. Ginsenosides and the β‑amyloid level
Aβ is the common name for several peptides that consist of 
36-43 amino acid residues. The main species are the following: 
One peptide with 40 amino acid residues (Aβ1-40) and another of 
42 amino acid residues (Aβ1-42) (44). Aβ is formed in the body 
from Aβ precursor protein (APP), which is a transmembrane 
protein that is concentrated in neurons through sequential prote-
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Table I. List of most known active components (ginsenosides) of Panax Ginseng C.A. Meyer.
No. Chemical compounds Structure
1 20S-protopanaxadiol 
 (3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-
 2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-
 pentamethyl- 2,3,5,6,7,9,11, 12,13,15,16, 
 17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol
 С30H52O3
 Мw = 460,743 g/mol 
2 Panaxadiol 
 (3S,5R,8R,9R,10R,12R,13R,14R,17S)-4,4,8,10,
 14-pentamethyl-17-[(2R)-2,6,6-trimethyloxan-2-yl]
 -2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclo-
 penta[a]phenanthrene-3,12-diol
 С30H52O3
 Мw = 460,743 g/mol 
3 Ginsenoside a1 (Panaxoside а1) (pseudoginsenoside F11)
 2-[2-[[(3S,6S,8R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-
 [(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,
 4,8,10,14-pentamethyl-2,3,5,6,7,9, 11,12,13,15,16,17-
 dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,
 5-dihydroxy- 6-(hydroxymethyl)oxan-3-yl]
 oxy-6-methyloxane-3,4,5-triol
 С42H72O14
 Мw = 801,024 g/mol 
 
4 Ginsenoside а2 (Panaxoside а2) (Ginsenoside RG1)
 (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)
 -3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-
 [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)
 oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,
 17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-
 (hydroxymethyl)oxane-3,4,5-triol
 С42H72O14
 Мw = 801,024 g/mol
5 Ginsenoside Rb1 (Panaxoside Rb1)
 2-O-β‑Glucopyranosyl‑(3β,12β)‑20‑[(6‑O‑β-D-
 glucopyranosyl-β-D-glucopyranosyl)oxy]-12-
 hydroxydammar-24-en-3-yl β-D-glucopyranoside
 С54H92O23
 Мw = 1109,307 g/mol 
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Table I. Continued.
No. Chemical compounds Structure
6 Ginsenoside Rb2 (Panaxoside Rb2) 
 (3β,12β)-20-[(6-O-α-L-Arabinopyranosyl-β-D-glucopyranosyl)oxy]
 -12-hydroxydammar-24-en-3-yl 2-O-β-D-glucopyranosyl-β-
 D-glucopyranoside, NSC 308878
 С53H90O22
 Мw = 1079,281 g/mol 
7 Ginsenoside Rb3 (Panaxoside Rb3) 
 (3β,12β)-3-[(2-O-β-D-Glucopyranosyl-β-D-glucopyranosyl)oxy]
 -12-hydroxydammar-24-en-20-yl6-O-β-D-xylopyranosyl-β-
 D-glucopyranoside
 С53H90O22
 Мw =1079,281 g/mol 
 
8 Ginsenoside Rg3 (Panaxoside Rg3) 
 (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,
 9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-
 methylhept -5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12, 13,15,16,
 17-dodeca-hydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-
 (hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
 С42H72O13
 Мw =785,025 g/mol 
9 Ginsenoside Rh2 (Panaxoside Rh2) 
 (3β,12β)-12,20-Dihydroxydammar-24-en-3-yl-β-D-glucopyranoside, 
 20(S)-Ginsenoside-Rh2
 С36H62O8
 Мw = 622,884 g/mol 
10 Ginsenoside Rh3 (Panaxoside Rh3) 
 (3β, 12β,20Z)-12-Hydroxydammar-20(22), 24-dien-3-yl-β-
 D-glucopyranoside
 С36H60O7
 Мw = 604,869 g/mol
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Table I. Continued.
No. Chemical compounds Structure
11 Ginsenoside Rg2 (Panaxoside Rg2)  
 (3β,6α,12β)-3,12,20-Trihydroxydammar-24-en-6-yl 2-O-
 (6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside
 С42H72O13
 Мw =785,025 g/mol 
12 Ginsenoside Rg4 (Panaxoside Rg4)
 (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S, 8R,9R, 10R,
 12R, 13R,14R,17S)-3, 12-dihydroxy-4,4,8,10, 14-pentamethyl-17-
 [(2Z)-6-methylhepta-2,5-dien-2-yl]-2, 3,5,6,7, 9,11,12,13,15,16,
 17-dodecahydro-1H-cyclopenta [a]phenanthren-6-yl]oxy]-4,
 5-dihydroxy-6-(hydroxymethyl) oxan-3-yl] oxy-6-methyloxane-3, 4,5-triol
 С42H70O12
 Мw =767,01 g/mol
13 Notoginsenoside R1 (Panaxoside R1)  
 (2S,3R,4S,5S,6R)-2-[(2S)-2-[(3S,5R,6S,8R,9R,10R,12R, 13R, 14R,17S)
 -6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,
 5R)-3,4,5-trihydroxyoxan-2-yl] oxyoxan-2-yl]oxy-3, 12-dihydroxy-4,4,
 8,10, 14-pentamethyl-2, 3,5,6,7,9,11,12,13,15,16, 17-dodecahydro-1H
 -cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-
 2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
 С47H80O18
 Мw = 933,139 g/mol
14 Ginsenoside Re (Panaxoside Re)
 3β,6α,12β)‑20‑(β-D-Glucopyranosyloxy)-3,12-dihydroxydammar-24-
 en-6-yl 2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside, 
 Chikusetsusaponin IVc, Ginsenoside B2, NSC 308877, Panaxoside Re
 С48H82O18
 Мw = 947,166 g/mol
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olysis with beta secretase 1 (BACE1) and γ-secretase (45). Aβ 
forms insoluble Aβ filaments, which subsequently stick together 
in the intercellular space into dense formations known as senile 
plaques (46). There is also an alternative, non-amyloidogenic 
pathway, in which the first cleavage of APP is catalysed, not 
by BACE1, but by α-secretase and the result is soluble amyloid 
precursor protein α (sAPPα), which exerts anti-apoptotic and 
neuroprotective effects (47,48).
Some ginsenosides are BACE1 inhibitors as molec-
ular docking and in vitro in studies have demonstrated. 
Their inhibitory ability decreases in a certain order: 
Rc>Rg1>Rb2>Rb1>Rg3>Re (36). Ginsenoside Re has not only 
been observed to reduce the activity of BACE1 and the expres-
sion of BACE1, but also to not affect the total levels of APP 
and sAPPα in a N2a/APP695 cell model (neuronal cells with 
an overexpression of APP) (49). It has also been shown that the 
decrease in BACE1 expression is associated with the activa-
tion of ginsenoside Re by peroxisome proliferator-activated 
receptor γ (PPARγ). Ginsenoside Rg1 is also a stimulator of 
PPARγ (50). The role of PPARγ in the pathogenesis of AD is 
not yet fully known.
Yan et al (51) demonstrated that ginsenoside Rd promoted 
the activation of the non-amyloidogenic pathway by activating 
estrogen receptor (ER). The methods they used in their study 
were as follows: 10 mg/kg ginsenoside Rd in ovariectomy/
ovariectomized (OVX) + ginsenoside Rd group and an 
equivalent volume of saline in the sham-operated group and 
OVX group were administrated intraperitoneally for two 
months, respectively. The MWM was used to examine the 
cognitive function of rats, and the levels of sAPPα and Aβ in 
the hippocampi were measured. The culture medium of HT22 
hippocampal neuronal cells was incubated with ginsenoside Rd, 
ER antagonist (ICI182.780), MAPK inhibitor (PD98059), or 
PI3K inhibitor (LY294002), respectively. The sAPPα levels 
were measured, and the expression levels of α-secretase, 
sAPPα, β-secretase, Aβ, phosphorylated AKT (p-AKT), total 
AKT, p-ERK, total ERK, p-ERα, total ERα, p-ERβ and total 
Erβ were examined by western blot analysis to investigate the 
estrogenic-like activity of ginsenoside Rd.
Accordingly, ginsenoside Rd was also found to attenuate 
cognitive and memory impairment, increase the levels of sAPPα 
and to reduce extracellular Aβ in OVX rats. In HT22 cells, ginsen-
oside Rd upregulated the sAPPα levels, which were inhibited by 
the inhibitors of the MAPK and PI3K pathways. In addition, the 
inhibitor of ER prevented the ginsenoside Rd-induced release 
of sAPPα and the activation of the MAPK and PI3K pathways. 
Ginsenoside Rd increased the expression of α-secretase and 
sAPPα, while it decreased the expression of β-secretase and 
Aβ. Moreover, ginsenoside Rd promoted the phosphorylation 
of ERα at the Ser118 residue (51). Similar results have also been 
obtained for ginsenoside Rg1 (52,53).
It has been demonstrated that ginsenosides Rd and Rg1 not 
only significantly reduce the level of Aβ, but also increase the 
level of sAPPα, as it has been shown in animal models of AD (54).
Huang et al (55) aimed to investigate the effects of 
Panax notoginseng saponins (PNS) on α-secretase and 
Table I. Continued.
No. Chemical compounds Structure
15 Ginsenoside Rh1 (Panaxoside Rh1)
 (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)
 -3,12-dihydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,
 4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-
 cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
 С36H62O9
 Мw = 638,883 g/mol 
16 Notoginsenoside ST4 
 (2S,3R,4S,5R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,
 5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-
 [(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,
 5,6,7,9,11,12,13,15,16, 17-dodecahydro-1H-
 cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-4,
 5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] oxyoxane-3,4,5-triol
 С47H80O17
 Мw = 917,14 g/mol 
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β-secretase involved in Aβ generation in SAMP8 mice. The 
results of their study revealed that PNS increased α-secretase 
activity perhaps by enhancing the level of ADAM9 expression, 
which itself was achieved by the upregulation of the expression 
of the ADAM9 gene. PNS significantly decreased the BACE1 
protein level by downregulating the level of BACE1 gene expres-
sion and consequently precluded the activity of β-secretase (56).
That study indicated that PNS modulated the expression 
levels of proteins and genes associated with α- and β-secretase, 
thereby increasing α-secretase activity and reducing β-secretase 
activity, which may be one of the mechanisms of action of PNS 
precluding Aβ generation. Accordingly, PNS may be a prom-
ising agent for AD (55).
Endres and Fahrenholz (57) noted in their research that 
a disintegrin and metallopeptidase domain 10 (ADAM10) 
presents a worthwhile target with respect to the treatment of a 
neurodegenerative diseases, such as AD. Animal models with 
an overexpression of ADAM10 revealed a beneficial profile of 
the metalloproteinase with respect to learning and memory, 
plaque load and synaptogenesis. Initially, ADAM10 was 
suggested to be an enzyme, shaping the extracellular matrix 
by cleavage of collagen type IV, or to be a tumour necrosis 
factor α (TNF-α) convertase. In a relatively short period of 
time, a wide variety of additional substrates [with amyloid 
precursor protein (APP) probably being the most prominent]
have been identified and the search is still ongoing. Hence, 
any side-effects concerning the therapeutic enhancement of 
ADAM10 α-secretase activity have to be considered (57).
However, in another stdy, the level of sAPPα was found 
to be higher in mice that were treated with ginsenoside Rh2 
than in the control group. Ginsenoside Rh2 inhibited the endo-
cytosis of APP and increased the distribution of APP on the 
cell membrane, thereby reducing the amyloid and increasing 
the non-amyloid pathway of cleaving APP (58). It has been 
proven that the level of cholesterol in neurons is involved in 
the pathogenesis of AD (59), and that the C-terminus of APP 
contains a cholesterol-binding domain (60).
Since it is known that the lipid raft is a specific cell membrane 
that is enriched with cholesterol, which plays an important 
role in the endocytosis of transmembrane proteins (61), and 
treatment with ginsenoside Rh2 significantly reduces the 
level of cholesterol in neurons, it has been concluded that the 
distribution of APP over the cell membrane is determined 
by the cholesterol in neurons (58). In addition to cholesterol, 
other lipids, such as phosphoinositides, are also involved in 
the pathogenesis of AD (62). One of the key phospholipids, 
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2], is formed 
by phosphatidyl inositol 4-phosphate (PI4P) phosphorylation 
using a specific enzyme, phosphatidyl inositol‑phosphate‑4 
kinase type 1γ. PI4P is formed via phosphatidylinositol by 
phosphatidylinositol-4-kinase 2α (PI4KIIα) (63). In vitro 
and in vivo, ginsenoside Rg3 has been observed to increase the 
levels of PI4P and PI(4,5)P2 by activating PI4KIIα (64). PI(4,5)P2 
contributes to the regulation of the mobility of transmembrane 
proteins in lipid rafts (65). In other words, PI(4,v5)P2 leads to 
changes in the fluidity and thickness of the membrane, and this, 
in turn, affects the activity of γ-secretase (66). Thus, high levels 
of PI4P and PI(4,5)P2, induced by ginsenoside Rg3, reduce the 
generation of Aβ by altering the activity of γ-secretase. The 
cognitive abilities of the animals in the MWM test following 
treatment with ginsenosides increased in all experiments, in 
relation to the control group with the AD model without treat-
ment with ginsenosides (51-54,58).
Substances from ginseng extracts directly or indirectly 
affect the activity of secretases. However, such an approach to 
AD treatment appears to provide low-probability outcomes, as 
demonstrated by the fact that a number of large pharmaceutical 
companies have completed the clinical trials of various secretase 
inhibitors ahead of time: Verubecestat (67), lanabecestat 
(BACE1 inhibitors) (https://www.astrazeneca.com/media-
centre/press-releases/2018/update-on-phase-iii-clinical-trials-of- 
lanabecestat-for-alzheimers-disease-12062018.html) and 
semagacestat (γ-secretase inhibitor) (68). There was no 
improvement in patients who were taking the BACE1 inhibitors 
compared to the placebo group. The first and second phases of 
the clinical trials of semagacestat revealed a decrease in the 
plasma Aβ1-42 concentration at 3 h after administration. However, 
the concentration increased by 300% after 15 h, while there 
was no reduction in the cerebrospinal fluid. Although semaga‑
cestat reduced the number of amyloid plaques, the cognitive 
functions of the patients taking semagacestat worsened compared 
with the placebo group (67,68; https://www.astrazeneca.com/
media-centre/press-releases/2018/update-on-phase-iii-clinical-
trials-of-lanabecestat-for-alzheimers-disease-12062018.html).
It has been proven in vivo that ginsenoside Rg3 reduces the 
level of Aβ by increasing the activity and expression of nepri-
lysin (69). Ginsenoside Rg1 has also been shown to increase 
the activity and expression of neprilysin (70). Neprilizin is one 
of the main enzymes that is capable of destroying Aβ.
It is known that protopanaxadiol (PPD)-type saponins are 
completely metabolized to 20-O-β-D-glucopyranosyl-20(S)-p
rotopanaxadiol (M1) by intestinal bacteria when taken orally; 
M1 and ginsenoside Rb1, as a representative of PPD-type 
saponins, were thus examined for cognitive disorders.
In a mouse model of AD induced by Aβ25-35 intracerebro-
ventricular injection, impaired spatial memory was recovered 
by the p.o. administration of ginsenoside Rb1 or M1 (71). 
Although the expression levels of phosphorylated NF-H and 
synaptophysin were reduced in the cerebral cortex and the 
hippocampus of mice injected with Aβ25-35, their levels in the 
ginsenoside Rb1- and M1-treated mice were almost completely 
recovered to those of the control levels. The potencies of the 
effects did not differ between ginsenoside Rb1 and M1 when 
administered orally, suggesting that most of the ginsen-
oside Rb1 may be metabolized to M1, and M1 is an active 
principal of PPD-type saponins for memory improvement. M1 
was shown to be effective in vitro and in vivo, indicating that 
ginseng drugs containing PPD-type saponins may reactivate 
neuronal function in AD by p.o. administration.
It has been demonstrated that AD is closely related to APP 
and presenilin-1 (PS1), which are overexpressed in AD (72). 
A study of UPLC/MS based metabolomics was conducted 
in order to better understand the mechanisms of action of 
ginsenoside Rg1 and Rg2, which counteract AD. The results 
revealed that ginsenosides Rg1 and Rg2 reduced rescue 
latency, compared to the AD model group, when cognitive 
function was tested in the MWM (71).
The impaired cognitive function and increased hippo-
campal Aβ deposition in mice with AD were ameliorated by 
ginsenoside Rg1 and Rg2. In addition, a total of 11 potential 
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biomarkers that are associated with the metabolism of lyso-
phosphatidylcholines (LPCs), hypoxanthine and sphingolipids 
were identified in the brains of mice with AD and their levels 
were partly restored following treatment with ginsenoside Rg1 
and Rg2. Ginsenoside Rg1 and Rg2 treatment influenced 
the levels of hypoxanthine, dihydrosphingosine, hexadec-
asphinganine, LPC C 16:0, and LPC C 18:0 in mice with AD. 
Additionally, G‑Rg1 treatment also influenced the levels of 
phytosphingosine, LPC C 13:0, LPC C 15:0, LPC C 18:1 and 
LPC C 18:3 in mice with AD (73).
A total of ten potential biomarkers were identified that 
were associated with the metabolism of lecithin, amino acids 
and sphingolipids in mice with AD. The peak intensities of 
LPC, tryptophan and dihydrosphingosine were lower, while 
those of phenylalanine were higher, in the mice with AD than 
in the control mice. Ginsenoside Rg1 treatment affected all 
three metabolic pathways, while ginsenoside Rb1 treatment 
affected lecithin and amino acid, but not sphingolipid metab-
olism. These data suggest that metabolomics has acquired a 
new method with which to discover the therapeutic benefits 
of ginsenosides in the treatment of AD (74).
Transgenic mice with AD have been used to study the 
protective properties of ginsenoside Rg1 on brain activity 
and synaptic plasticity, using conditional reflex fading and the 
western blotting technique. The results revealed that long-term 
memory improves following treatment with ginsenoside Rg1. 
Furthermore, ginsenoside Rg1 did not have a negative effect 
on normal diet and weight, while also inhibiting the levels of 
C-terminal fragments (CTF), phosphorylated τ-protein (p-Tau) 
and Aβ1-42 in mice with AD. Ginsenoside Rg1 was also able 
to improve the expression of brain-derived neurotrophic 
factor (BDNF) and tyrosine receptor kinase B (TrkB) in the 
hippocampus. The results revealed that ginsenoside Rg1 exerted 
a neuroprotective effect via the activation of the BDNF-TrkB 
pathway and that weakened the expression of AD-associated 
proteins (75).
Furthermore, ginsenoside Rg1 has been found to increase 
the expression of N-methyl-D-aspartate receptor 1 (NR1) and 
N-methyl-2B D-aspartate (NR2B), while also attenuating 
the formation of NFTs, which directly affect the processes 
of learning and memory in mouse models with AD (76). 
It was discovered in recent studies that reproductive sex 
hormones, particularly oestrogen, play an important role 
in the pathogenesis of AD. The rapid decline in oestrogen 
levels in postmenopausal women increases susceptibility to 
AD (77-79).
Thus, the absence of oestrogen can be a risk factor for 
AD. Zhang et al conducted a successful study to examine the 
neuroprotective effects of ginsenoside Rg1 on an OVX and 
D-galactose (D-gal)-injected rat model of AD (54). The results 
revealed that ginsenoside Rg1 not only restored impaired 
cognitive activity and positively affected spatial learning and 
memory, but also reduced the production of Aβ1-42 in the rats 
with AD. Seven weeks after surgery, ADAM10 expression in 
the hippocampus of the rats with AD was markedly decreased, 
while BACE1 expression increased compared with that in 
the sham-operated group (P<0.05). The levels of cleaved 
caspase-3 were increased in the hippocampus of rats with AD. 
Ginsenoside Rg1 and E2 treatment increased the ADAM10 
level, while it reduced the BACE1 level and apoptosis. 
Moreover, moderate-dose i.e., 10 mg/kg/day and high-dose 
i.e., 20 mg/kg/day ginsenoside Rg1 exerted more poten effects 
than low-dose i.e., 5 mg/kg/day ginsenoside Rg1 (54). It is 
well known that chronic stress restrictions (in animals) can 
accelerate the process of AD generation and development. 
Ginsenoside Rg1 protects from oxidative damage by reactive 
oxygen species (ROS) and inhibits the expression of NADPH 
oxidase 2 (NOX2), p47phox and RAC1 (80).
The association between ginsenoside Rg1 and the endo-
plasmic apoptotic pathway, as mediated by the reticulum, 
has also been examined in a rat model of AD. The results 
revealed that ginsenoside Rg1 reduced the accumulation of 
NFTs and the number of terminal deoxynucleotide trans-
ferase‑mediated dUTP filamentous ends that mark positive 
cells in mice with AD. More importantly, ginsenoside Rg1 
inhibited the activation of apoptosis-associated phosphory-
lated-c-Jun N-terminal protein kinase (p-JNK) and reduced 
the expression of glucose-regulated protein 78 (Grp78). 
Consequently, ginsenoside Rg1 exerted a neuroprotective 
effect by inhibiting the accumulation of NFTs and Aβ via 
inhibition of the ER stress-mediated pathway. The blocking 
of this pathway was triggered by the inositol-requiring 
enzyme-1 (IRE-1) and tumour necrosis factor receptor-
associated factor 2 (TRAF2) pathway, as a result of the 
inhibition of the expression of p-JNK (81).
A scientific study found that pseudoginsenoside F11 (PF11), 
one of the components of ginseng, exerted a neuroprotective 
effect and enhanced the activity of neurons (82). Another 
study demonstrated that PF11 reduced the latency of rescue in 
the MWM and blocked the reduction of stepwise latency in 
the step test for Aβ11-42 and APP/PS1 mice. In addition, PF11 
inhibited APP expression and the production of Aβ11-42 in the 
hippocampus and cortex of APP/PS1 mice. PF11 significantly 
increased the activity of superoxide dismutase (SOD) and 
glutathione peroxidase and reduced the amount of malo-
ndialdehyde (MDA). In addition, PF11 reduced the expression 
of JNK2, p53 and cleaved caspase-3. Thus, the improved 
recognition that is observed when subjects are exposed to 
ginsenoside PF11 may be associated with anti‑inflammatory, 
anti-apoptotic and inhibitory effects on amyloid genesis (83). 
By analogy, it has been found that ginsenoside R1 exerts a 
protective effect against Aβ-neurotoxicity (84).
In a previous study, ginsenoside Rb1 also reduced the 
presence of Aβ1-42 in the area of the cortex and hippocampus 
as well as improving the ability to learn in mice with AD (85). 
It is well known that cyclooxygenase 2 (COX-2), IkB-α and 
neuronal nitric oxide (NO) synthase (nNOS) are markers of 
neuroinflammation. Ginsenoside Rb1 reduced the number of 
COX-2-positive cells and positive IkB-α cells and increased 
the number of nNOS-positive cells in the hippocampus, as 
compared to the model group. The neuroprotective effect of 
ginsenoside Rb1 may thus be associated with anti‑inflammatory 
markers in the hippocampus of mice with AD (85). More 
importantly, ginsenoside Rb1 has been observed to be more 
rapidly absorbed than ginsenoside Re and Rg1 (86). The effect 
of ginsenoside Rb1 may therefore be more potent than that 
of the other ginsenosides. In addition, ginsenoside Rb1 also 
demonstrated higher activity against neurotransmitters. For 
example, ginsenoside Rb1 has a higher absorbing activity against 
ONOO(-) than ginsenoside Rb2, Rc, Re, Rg1 and Rg3 (36).
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Studies have shown that ginsenoside Rd can improve 
learning ability and memory, and can reduce neuronal death 
and loss in the CA1 region of the hippocampi of mice with AD. 
Moreover, ginsenoside Rd decreased the expression of ionized 
calcium‑binding adaptor molecule 1 (Ibal), glial fibrillar acid 
protein (GFAP), interleukin (IL)-1β, IL-6, TNF-α, caspase-3 
and S100β mRNA. Ginsenoside Rd has also been observed 
to increase IL-10 and HSP70 mRNA expression levels (87). 
Furthermore, ginsenoside Rd has been shown to inhibit the 
expression of NF-κB p65, which is an important marker 
of the NF-κB pathway (88). These findings indicate that the 
anti‑inflammatory, antioxidant and anti‑apoptotic effects of 
ginsenoside Rd are responsible for its neuroprotective effects.
AChE and BChE play a significant role in AD. The 
inhibition of AChE and BChE provides additional benefits 
to the treatment of AD. Ginsenosides Rb1, Rb2, Rc, Re, Rg1 
and Rg3 have been shown to exert significant inhibitory effects 
against AChE and BChE. The Re compound of the series 
of ginsenosides inhibits the activity of AChE with optimal 
results (36). It has been demonstrated that ginsenosides 
exert neuroprotective effects via acting on neurotransmitters 
in AD. For example, ginsenosides can increase the levels of 
γ-aminobutyric acid, Ach and dopamine and reduce the levels 
of glutamate and aspartic acid in the hippocampus and cerebral 
cortex. Moreover, ginsenosides can increase the level of glycine 
and serotonin in the blood (43). These studies provide a novel 
method for AD treatment.
Apart from ginsenosides, the glycolipoprotein fractions of 
ginseng extracts (gintonin) have also been the subject of an 
AD model study, which made five observations to indicate that 
gintonin counteracts the development of AD: Gintonin has 
been shown to promote the production of sAPPα by activating 
ADAM10, inhibit Aβ production in a dose-dependent manner, 
activate PI3K and AKT, and also not only to alleviate memory 
impairment caused by Aβ neurotoxicity, but also reduces the 
deposition of amyloid plaques in a mouse model of AD (89).
6. Ginsenosides and calcium ion levels in neurons
The mechanism of the neuronal damage that is caused by an 
increase in the intracellular level of calcium ions (Ca2+), which 
is in turn induced by glutamate, has been well studied (90). An 
increase in Ca2+ levels leads to the excessive stimulation of proteo-
lytic enzymes, an increase in lipid peroxidation and an increase 
in the generation of ROS and nitrogen (91,92), thereby contrib-
uting to the excitotoxic process. Aβ not only causes the addition 
of new ion channels in the cell membrane, but also promotes the 
phosphorylation of existing calcium channels, thereby increasing 
the flow of calcium and initiating neurodegeneration (93). Aβ 
increases the phosphorylation of membrane-bound proteins and 
decreases the phosphorylation of cytosolic proteins, via MAPK, 
with the result that the intracellular level of Ca2+ increases (94). 
Ginsenoside Rg2 can significantly reduce the intracellular 
level of Ca2+ and ROS that is caused by Aβ25-35 in the PC12 cell 
model (95). In another study, ginsenoside Rg2 has been found to 
reduce not only the level of Ca2+, but also the lipid peroxidation 
that is caused by glutamate (96).
Notably, while ginsenoside Rb1 can reduce the intracellular 
level of Ca2+ when it was increased by administering Aβ25-35, the 
intracellular level of Ca2+ in healthy cells is not affected (97). 
Ginsenoside Rg1 has been observed to suppress the sensitivity of 
calcium channel activation to high values of membrane potential 
in an animal model of AD [Sprague Dawley (SD) rats administered 
Aβ25-35]. This effect disappears when ginsenoside Rg1 is used 
together with the MAPK inhibitor, PD98059 (98).
Quan et al (98) demonstrated that Rg1 treatment signifi-
cantly reduced peak ICa, HVA densities, inhibited the sensitivity 
of channel activation to voltage, and enhanceed the sensitivity 
of channel inactivation to voltage; these effects of Rg1 were 
effectively inhibited by the MAPK inhibitor, PD98059. This 
indicated that Rg1 reduced Aβ-induced HVA calcium channel 
currents via MAPK in hippocampal neurons. The resulting 
reduced calcium influx may downregulate the level of calcium 
ions in the neurons and attenuate the neurotoxicity of Aβ. In 
summary, the data of that study demonstrated that Rg1 can 
reduce HVA calcium channel currents via MAPK in hippo-
campal neurons in Aβ-exposed brain slices (98).
As mentioned above, the intracellular concentration of Ca2+ 
is an important indicator of neurological disorders. Increased 
Ca2+ levels may increase the manifestation of epilepsy. 
Ginsenosides, in general and ginsenoside Rg3, in particular, 
can inhibit an increase in Ca2+ that is induced by Mg2+. 
Ginsenosides can modulate the disrupted Ca2+ homeostasis by 
inhibiting the glutamate ionotropic receptors that selectively 
bind N-methyl-D-aspartate (NMDA receptors) (99). In addition, 
oxidative stress can lead to hippocampal degeneration. It is 
noteworthy that ginsenosides reduce the oxidative stress that 
acts upon the parts of the nerve ending that correspond to 
the synapse (synaptosomes), and reduce the synaptic vesicles 
of dose-dependent presynaptic terminations. Moreover, it is 
not adenosine A1 receptors or adenosine A2B receptors, but 
adenosine A2A receptors that play an important role in the 
fight against epilepsy. Thus, ginsenosides exert an antiepileptic 
effect that they exert by activating the Adenosine-A2A 
receptors (100) (Table II).
An increase in the intracellular levels of Ca2+ mediates 
the activation of calcium-dependent enzymes, such as calpain 
(calcium-dependent non-lysosomal cysteine proteases). 
Calpain II is involved in the regulation of the apoptosis of 
certain cell types and performs this role by interacting with 
cysteine protease caspase-3, which has been identified as a 
key factor in apoptosis (101). The expression of calpain II 
and caspase-3 in vivo has been found to be reduced under the 
influence of ginsenoside Rg2 (96). The decrease in the activity 
of caspase-3 is caused by an increase in the B-cell lymphoma 
protein 2 (Bcl-2)/Bcl-2-associated X-protein (Bax) ratio, which 
is caused by ginsenoside Rg2 (95).
Caspase-3 is involved not only in the regulation of cell 
apoptosis, but also in the proteolytic cleavage of APP, with 
the formation of Aβ. The caspase-3-mediated proteolysis 
site is located in the cytoplasmic tail of APP, and cleavage 
at this site occurs in vivo in the hippocampal neurons 
following acute excitotoxic or cerebral ischemia reperfusion 
injury (102). An increased caspase-3 activity and expression 
have been observed in rat models of AD; however, the activity 
and expression of caspase-3 decreases markedly following 
treatment with ginsenosides Rg1 and Rd (81,87). The protein 
fraction, extracted from 4-year-old ginseng root, is also able 
to reduce the expression of caspase-3, as well as increase the 
Bcl-2/Bax ratio (103).
MOLECULAR MEDICINE REPORTS  19:  2975-2998,  2019 2985
Other components of ginseng, apart from ginsenosides, 
are capable of influencing the intracellular level of Ca2+. 
Quercetin 3-O-β-D-xylopyranosyl-β-D-galactopyran
osyl (QXG) has been isolated from Panax notoginseng root. 
Of note, a previous study demonstrated that following the 
introduction of Aβ into cortical neurons and PC12 cells 
alone, the intracellular level of Ca2+ w not altered. However, 
following pre-treatment with QXG, the level of Ca2+ which 
Table II. Pharmacological activity and mechanism of ginsenoside action on epilepsy, depression and reperfusion injury of the 
brain.
Pharmacological
intervention Ginsenosides Impact mechanism Authors/(Refs.)
Anti-epileptic effect All ginsenosides Activation of adenosine-A2A receptors  Shin et al (100)
  Rg3 Modulation of Ca2+ disrupted homeostasis via  Doody et al (68)
  the inhibition of the nanomethylenediamine receptor 
Anti-depressant Rg1 Increased levels of phosphorylation of protein kinase A Jiang et al (160),
effect  and levels of phosphorylation of the cAMP-response Liu et al (161)
  elements of the activating protein. Expression of the
  hippocampal transmission pathway of the neurotrophic
  factor of the brain, hippocampal neurogenesis
  All ginsenosides Increased plasma ACTH levels and CORT blood levels Wang et al (151), 
   Kang et al (153)
  Rb1 Activation 5-HT2A receptor  Yamada et al (152)
  Rb3 Stops the process of reducing the mass of the hippocampus Cui et al (162)
  of the brain and the level of BDNF in the hippocampus
  CК Activation 5‑HT2A receptor for the manifestation of  Zhang et al (154), 
  the antidepressant effect, the regulation of levels of  Yamada et al (152)
  NA, ACTH and CORT in the brain.
  Rg3 Facilitation of the hippocampal-signalling pathway of Zhang et al (154),
  BDNF, regulation of thelevels of NA,  You et al (155)
  ACTH and CORT in the brain area.
Protection against Rg1 Decreases levels IL‑1β, TNF‑α and HMGB1, suppresses the Bao et al (126),
cerebral ischemia  expression of cleaved caspase-3 and cleaved caspase-9. Zhou et al (127)
reperfusion injury  Downregulation of proteinase-activated receptor-1 (PAR-1)  Yang et al (129),
  mRNA levels activated by protease Xie et al (131),
   Sun et al (132),
   Huang et al (150)
  Rb1 Cancels the signalling pathway activation of NF-κB and the Huang et al (150)
  increase in TNF-α and IL-6 levels in the ischemic hemisphere. Zeng et al (149)
  It prevents the reduction of thioredoxin-1 and
  superoxide dismutase and improves the expression of
  HSP70, Akt and the p-NF-κB p65 block when occluding
  the middle cerebral artery.
  Rd Improves neuronal viability by inhibiting the overactive Liu et al (156),
  phosphorylation of NMDAR 2B and reducing levels Xie et al (157)
  of expression in the cell membrane
  Re Neuroprotective action by significantly reducing  Chen et al (158)
  MDA and increasing the activity of H+-ATPhase 
  Rg3 Reduces the expression of calpain I and caspase-3 He et al (159)
  mRNA in the CA1 region of the hippocampus
BDNF, brain-derived neurotrophic factor; NA, noradrenaline; ACTH, adrenocorticotropic hormone; CORT, corticosterone; HMGB1, high mobility 
protein group; PAR-1, protein and receptor-1 mRNA; NF, nuclear factor; HSP70, heat shock protein 70; NMDAR 2B, N-methyl-d-aspartate 
receptor 2B; MDA, malondialdehyde; TNF-α, tumour necrosis factor α.
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was increased by Aβ was decreased by 50%. QXG also 
reduced the Aβ levels and caspase-3 activity in vivo (104).
7. Ginsenosides and neuroinflammatory processes
NF-κB is a transcription factor with various functions that is 
closely associated with the inflammatory response, the immune 
response and other pathological and physiological processes. 
NF-κB is in the cytoplasm in an inactive form in a normal state. 
When NF-κB is activated and enters the nucleus, it binds to 
target genes and induces transcription (105). NF-κB activates 
the transcription of TNF-α, various ILs (IL-1β and IL-6) and 
other target genes during inflammation, and contributes to the 
production of cytokines. It has also been found that NF-κB 
is associated with neurodegenerative diseases and is activated 
in the cerebral cortices of patients with AD (106). It has been 
shown, for ginsenoside Rb1 (107) and Rg5 (41) in vitro and for 
ginsenoside Rd (88) in vivo, that these ginsenosides are capable 
of reducing the expression of anti‑inflammatory factors (IL‑1β, 
IL-6 and TNF-α) and increasing the expression of IL-10 (for 
Rb1 and Rd) by suppressing the activation of NF-κB.
COX-2 is a key enzyme in the synthesis of prostaglandins 
and is an important mediator of inflammation (108). NO is a 
short-lived neurotransmitter that plays an important role in 
learning and memory mechanisms. As a result, impaired NO 
synthesis can lead to memory impairment and a decrease in 
learning ability (109). The fact that a number of inflammatory 
molecules can regulate the expression of NO synthases [NO 
synthase 1 (neuronal) (NOS1) and NO synthase 1 (induc-
ible) (NOS2)] suggests that NOS should be considered a 
neuroinflammatory marker (110). The levels of COX‑2 and 
NOS2 have been observed to increase significantly in models 
of AD (Wistar rats, administration of either Aβ or strepto-
zocin), while the level of NOS1 decreases compared to the 
control group. However, treatment with ginsenoside Rg5 
lowers the levels of COX-2 and NOS2 compared to the 
control values (41), and the level of COX-2 also decreases 
following treatment with ginsenoside Rb1, and the level of 
NOS1 increases (85).
Li et al examined the effect of ginsenoside Rg2 on 
neurotoxic activities induced by glutamate in PC12 cells (96). 
The results revealed that glutamate decreased cell viability, 
increased intracellular Ca2+ lipid peroxidation (the excessive 
production of MDA and NO) and the protein expression levels of 
calpain II, caspase-3 andAβ1-40 in PC12 cells. Ginsenoside Rg2 
significantly attenuated the glutamate-induced neurotoxic 
effects upon these parameters at all doses tested. Their study 
suggested that ginsenoside Rg2 exerted a neuroprotective 
effect against glutamate-induced neurotoxicity through 
mechanisms related to anti-oxidation and anti-apoptosis. In 
addition, the inhibitory effect of ginsenoside Rg2 against the 
formation of Aβ1-40 suggested that ginsenoside Rg2 may also 
represent a potential treatment strategy for AD (96).
Li et al investigated and evaluated the neuroprotective effects 
of ginseng protein (GP) and its possible mechanisms of action 
in a cellular and animal model of AD. The results demonstrated 
that GP (10‑100 µg/ml) significantly improved the survival rate 
of neurons and reduced cell apoptosis and the mRNA expression 
of caspase‑3 and Bax/Bcl‑2. In addition, GP (0.1 g/kg) signifi-
cantly shortened the escape latency, prolonged the crossing 
times and the percentage of residence time; reduced the level 
of Aβ1-42 and p-Tau, the activity of t-NOS and iNOS, and the 
content of MDA and NO, improved the activity of SOD, the 
concentration of cyclic adenosine monophosphate (cAMP) and 
the protein expression of p-PKA/PKA and cAMP response 
element binding protein (p-CREB/CREB) (103).
Ginseng extracts also exhibit antioxidant properties in AD 
models. In fact, ginsenoside Rg2 has been shown to decrease 
the concentration of MDA (a marker of lipid peroxidation) (96) 
and the level of ROS in vivo (95). The GP fraction activates 
SOD (antioxidant enzyme) and reduces the concentration of 
MDA in vitro (103). Furthermore, QXG prevents the forma-
tion of H2O2-induced ROS generation in a dose-dependent 
manner in vitro (104).
8. Ginsenosides and the PI3K/Akt signalling pathway
As mentioned above, ginseng root components are able to affect 
the PI3K/Akt signalling pathway. The PI3K/Akt signalling 
pathway is one of the most important signalling pathways with 
which cells can avoid apoptosis and it plays a significant role 
in oxidative stress in AD. Kashour et al (110) examined the 
role of the late Simian virus 40 transcription factor (LSF), 
in anti-apoptotic APP pathways. The expression of wild-type 
human APP (hAPPwt) inhibited staurosporine (STS)-induced 
apoptosis and this inhibition was further enhanced by the 
expression of LSF. Thus, Kashour et al (111) established 
a connection between APP, LSF and AD. Akt (p-Akt) 
hyperphosphorylation regulates apoptotic factors, such as 
Bcl-2 and Bax, downstream signalling pathways, which allows 
for the regulation of apoptosis (112). The suppression of the 
PI3K/Akt signalling pathway promotes cell apoptosis, while 
the activation of the PI3K/Akt signalling pathway leads to the 
phosphorylation of the Akt cascade, which, in turn, protects the 
cells from oxidative stress (113).
Cui et al examined the protective effects of ginsen-
oside Rg2 on Aβ25-35-induced neurotoxicity to PC12 cells and 
identified a potential molecular signalling pathway involved. 
Ginsenoside Rg2 attenuated the cleavage of caspase-3 induced 
by Aβ25-35 thereby improving cell survival and significantly 
enhanced the phosphorylation of Akt in PC12 cells. Additionally, 
pre-treatment with PI3K inhibitor, LY294002, completely 
abolished the protective effects of ginsenoside Rg2 against 
Aβ25-35‑induced neuronal cell apoptosis. These findings unam-
biguously suggested that the protective effect of ginsenoside Rg2 
against the Aβ25-35-induced apoptosis of PC12 cells was associ-
ated with activation of the PI3K/Akt signalling pathway (95).
Li et al examined the therapeutic effect of GP on AD and 
its association with the PI3K/Akt signalling pathway in order to 
elucidate the mechanisms underlying the neuroprotective effects 
of ginseng (114). It was found that the cognitive abilities of the 
rats with AD were increased and the level of Aβ was also reduced 
by treatment with GP. GP also reduced the content of Aβ1-42 and 
p-Tau, and increased the mRNA and protein expression of PI3K, 
p-Akt/Akt and Bcl-2/Bax in the hippocampus (114).
9. Ginsenosides and the formation of neurofibrillary tangles
As mentioned above, AD is characterized by the accumula-
tion of NFTs in cerebral tissue. NFTs are mainly composed of 
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hyper p-Tau. τ-protein is a microtubule-related protein that is 
expressed in the central nervous system. It induces microtubule 
assembly and stabilisation. However, excessive p-Tau forms 
NFTs and leads to synaptic dysfunction, neuronal degeneration 
and cognitive impairment (115). In addition, abnormal hyper-
phosphorylation renders the τ-protein resistant to proteolytic 
degradation, which leads to the gradual accumulation of p-Tau 
in the cell and promotes the formation of NFTs. The inhibition 
of p-Tau can therefore be a potential therapeutic strategy for the 
prevention of AD.
Okadaic acid (OKA), a potent phosphatase inhibitor, 
often used to mimic the symptom of AD damaged by 
NFTs, was used in the study by Song et al to examine the 
effects of ginsenoside Rg1 on memory improvement and 
related mechanisms in SD rats. According to their study, it 
can be concluded that ginsenoside Rg1 protects rats from 
OKA-induced neurotoxicity. The possible neuroprotective 
mechanisms may be that Rg1 decreases OKA-induced memory 
impairment through the glycogen synthase kinase 3 (GSK3)
β/Tau signalling pathway and/or by attenuating Aβ formation. 
Thus, their study indicates that ginsenoside Rg1 may be a 
potential prophylactic drug for AD (116).
Plattner et al noted in their study that the hyperphosphoryla-
tion of the microtubule-associated protein Tau is a characteristic 
feature of neurodegenerative tauopathies, including AD (117). 
The overactivation of proline-directed kinases, such as 
cyclin-dependent kinase (CDK)5 and GSK3, has been impli-
cated in the aberrant phosphorylation of Tau at proline-directed 
sites. The results obtained in the study by Plattner et al prove the 
role of GSK3 as a key mediator of Tau hyperphosphorylation, 
whereas CDK5 acts as a modulator of Tau hyperphosphoryla-
tion via the inhibitory regulation of GSK3 (117).
Li et al (118) сonvincingly proved in their study that pre‑
treatment of adult male SD rats with ginsenoside Rd (10 mg/kg 
for 7 days) or that of cultured cortical neurons (2.5 or 5 mol/l 
for 12 h) reduced OKA-induced neurotoxicity and Tau 
hyperphosphorylation by enhancing the activities of protein 
phosphatase 2A. The results of their study implied that ginsen-
oside Rd protected the SD rats and cultured cortical neurons 
against OA-induced toxicity (118).
Zhang et al (119) subjected SD rats to focal cerebral 
ischemia. Treatment with ginsenoside Rd attenuated the 
ischemia-induced enhancement of Tau phosphorylation 
and ameliorated behavioral impairment. Furthermore, they 
revealed that ginsenoside Rd inhibited the activity of GSK-3β, 
the most important kinase involved in Tau phosphoryla-
tion, but enhanced the activity of PKB/Akt, a key kinase 
suppressing GSK-3β activity (119).
A decrease in the activity of protein phosphatase 2A (PP-2A) 
in the cerebrum of individuals with AD is another cause 
of τ-protein hyperphosphorylation. PP-2A is the key 
serine/threonine phosphatase and presents broad substrate 
specificity. It is involved in the dephosphorylation of the 
τ-protein (120). It has been proven that ginsenoside Rd is 
capable of activating PP-2A in vitro and in vivo, and thereby 
reducing the level of p-Tau (121).
It has also been demonstrated that various ginsenosides 
can reduce the level of p-Tau and prevent the formation of 
p-Tau (43). However, to date, there is no clear understanding of 
the mechanisms through which this occurs.
Ginsenoside Rg1 has been observed to reduce the formation 
of NFTs in a study on transgenic rats that have increased 
APP and Aβ production. The authors of that study associated 
the accumulation of NFTs with brain-cell apoptosis (81). 
Furthermore, it was shown that ginsenoside Rg1 blocked the 
stress-apoptotic pathway that was caused by the disruption of 
the endoplasmic reticulum. The blocking of this pathway was 
initiated by the inhibition of the expression of IRE-1, factor 2, 
which is associated with TRAF2 and p-JNK. Moreover, as 
mentioned above, ginsenoside Rg1 inhibited apoptosis by 
increasing the Bcl-2/Bax ratio (81,119).
In another study, it was assumed that the mechanism of 
NFTs accumulation was mediated by the influence of nepri-
lysin and protein kinase A (PKA) on the phosphorylation 
of the τ-protein. Ginsenoside Rg1 reduced the activity and 
expression of PKA and increased the activity and expression 
of NEP at the same time, thereby inhibiting τ-protein hyper-
phosphorylation (70).
10. Ginsenosides and other factors
Elevated levels of Aβ can inhibit the expression of neurotrophic 
factors, such as BDNF and insulin-like growth factor-1 (IGF-1). 
It has been found that BDNF is a synaptic-plasticity regulator 
that is involved in memory and cognitive functions. It plays a 
role in several events that constitute the pathological cascade 
in AD (122). A decrease in the level of IGF-1 in the brain is 
considered an important factor in the development of cognitive 
impairment and Aβ deposition (123). Ginsenoside Rg5 is able 
to increase the expression of BDNF and IGF-1, as shown in 
a study on a mouse model of AD. Ginsenoside Rg1 has not 
only been recorded to increase BDNF expression in a trans-
genic mouse model of AD, but also to activate TrkB, which 
acts as the BDNF receptor, thereby activating the BDNF/TrkB 
pathway (75). The effective transcription of BDNF only occurs 
following the activation of four transcription factors, including 
CREB (124). In most cases, CREB dysfunction plays a signifi-
cant role in alterations in BDNF expression. The activation of 
CREB occurs mainly via phosphorylation at Ser133 by PKA, 
the activity of which is suppressed in the model of AD induced 
by Aβ. In fact, it has been shown that ginsenoside Rg1 increases 
the expression of BDNF via the phosphorylation of CREB and 
the activation of PKA (125).
Bone marrow stem cell (BMSC) transplantation is currently 
used in the treatment of cerebral ischemic disease. However, 
this method also presents some disadvantages, such as the 
low conversion rate of neural cells and weak proliferation 
ability (126). Ginsenoside Rg1 is a possible therapeutic agent 
for cerebral ischemia as its molecules are small enough to pass 
through the blood-brain barrier (127).
Reperfusion in cerebral ischemia can cause a significant 
disruption to the nervous system, and can increase the water 
content in the brain and the volume of infarction. Notably, 
ginsenoside Rg1 can improve nervous system deficiency, reduce 
cell apoptosis and increase the sensitivity of neuron‑specific cell 
enolase and the gliofibrillary acidic protein of cells. Moreover, 
ginsenoside Rg1 not only significantly increases the protein 
level of Bcl-2, but also lowers the protein level of Bax (126).
The combined use of ginsenoside Rg1 and BMSC trans-
plantation improves the quality of brain tissue by enhancing 
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the neuro-like cell differentiation and the anti-apoptotic effect 
of ginsenoside Rg1 in reperfusion injury in cases of cerebral 
ischemia (126).
Ginsenoside Rg1 has also been found to improve neuro-
logical injury conditions by suppressing the expression of 
aquaporin 4 (127).
It is well known that the inflammation and apoptosis of 
neurons often occur with reperfusion injury following cerebral 
ischemia. Kashour et al clearly indicated in their study that 
the expression of dominant-negative late Simian virus 40 
transcription factor (LSF) led to a marked increase in stauro-
sporine‑induced cell death that was significantly blocked by 
hAPPwt. These effects of Alzheimer's APP were accompanied 
by LSF nuclear translocation and dependent gene transcrip-
tion. The activation of LSF is dependent on the expression of 
hAPPwt and is inhibited by the expression of dominant-nega-
tive forms of either phosphoinositide 3-kinase or Akt. These 
results demonstrate that LSF activation is required for the 
neuroprotective effects of APP via PI3K/Akt signalling (111).
Chem-oxygenase-1 (HO-1) is one of the downstream 
effectors of PPARγ. The PPARγ/HO-1 signalling system can 
inhibit apoptosis and inflammation. The association between 
ginsenoside Rg1 and the PPARγ/HO-1 signalling system in 
cerebral ischemic reperfusion injury has been investigated. 
Li et al (128) hypothesized that the neuroprotective effects 
of ginsenoside Rg1 occur through PPARγ signaling in the 
ischemic brain. They demonstratyed that Rg1 markedly 
increased PPARγ expression in ischemic rats and in the cortical 
neurons of cerebral cortical neuron ischemic injury model rats. 
They also found that the selective PPARγ antagonist, GW9662, 
reduced PPARγ expression, suggesting that Rg1 may be a 
potent PPARγ agonist.
With the use of the middle cerebral artery occlusion rat 
model with cerebral ischemia/reperfusion injury, Li et al (128) 
also observed that Rg1 effectively reduced neurological 
disorders and swelling of the brain in cerebral ischemic 
injury. These results are in accordance with those of other 
studies which demonstrated the effectiveness of Rg1 as a 
neuroprotector in various models of cerebral ischemic injury, 
including neurological deficits (129,130).
.
In addition, ginsenoside Rg1 has not only been found 
to reduce the levels of IL-1β, TNF-α and high mobility 
group box protein 1 (HMGB1), but also to suppress the 
expression of cleaved caspase-3, cleaved caspase-9 and the 
receptor for advanced glycation end products (RAGE) in 
rat models (129). The infarct volume of the cerebrum and 
the permeability of the blood-brain barrier decreases with 
cerebral ischemic disease following exposure to ginsen-
oside Rg1. Ginsenoside Rg1 may attenuate neurological 
injury, the brain infarct volume and the blood-brain barrier 
permeability induced by focal cerebral ischemia in rats, and 
its neuroprotective mechanism is related to the downregu-
lation of protease activated receptor-1 (PAR-1) expression. 
The permeability of the blood-brain barrier also increases 
with an increase in PAR-1 expression (131).
Moreover, astrocytes play an important role in the ischemic 
death of neurons. Although ginsenoside Rg1 does not alter the 
viability of astrocytes, its effect can weaken apoptosis and inhibit 
the intracellular overload of Ca2+ in astrocytes. In addition, 
ginsenoside Rg1 can reduce the loss of the transmembrane 
potential of the mitochondria and ROS production in 
astrocytes (132).
Metabolomic analyses have been performed in a number 
of studies, and substances whose level varied in the AD 
model have been identified and recovered under the action of 
various ginsenosides. In a previous study, a total of 10 poten-
tial biomarkers that were associated with the metabolism of 
lecithin, amino acids, and sphingolipids were identified in 
mice with AD based on metabolomics. These biomarkers in 
the plasma of mice with AD were disrupted. Following treat-
ment with ginsenoside Re, the disrupted metabolic profiling 
was restored back to control-like levels, indicating that 
the protective effect of ginsenoside Re in AD was exerted 
through these pathways (133). In that study (133), the levels 
of hexadecasphinganine and phytosphingosine were both 
decreased in the plasma of mice with AD as compared to the 
control mice. Following treatment with ginsenoside Re, the 
levels of these two metabolites were significantly elevated. 
Thus, the results suggest that mice with AD have impaired 
sphingolipid metabolism, and therefore plasma sphingolipids 
can also be utilized as indicators of therapeutic response. The 
therapeutic effects of ginsenoside Re on mice with AD are 
exerted through the modulation of sphingolipid metabolic 
processes (133).
Ginsenosides Rg1 and Rb1 increase the concentrations of 
tryptophan, di-hydrosphingosine (Rg1 only), various lysosfati-
dylcholines (C22: 6, C20: 4, C18: 2, C16: 0, C18: 1 and C18: 0), 
and lower the levels of phenylalanine (53). Ginsenoside Rg2 
increases the concentrations of hypoxanthine, dihydrosphingo-
sine, hexadecasphinganine and lysosfatidylcholine C16: 0 and 
C18: 0 (73).
A comparative proteomics analysis was performed on 
a model of AD using the stable isotope labelling by amino 
acids in cell culture (SILAC) in order to examine the poten-
tial defence mechanisms of ginsenoside Rb1. Forty proteins 
were found that exhibited significant changes after the treat-
ment of cells, into which Aβ had previously been introduced, 
with ginsenoside Rb1. As a result, the authors suggested that 
proteins, such as adenylyl cyclase associated protein 1, the 
isoform 2, the subunit β F-actin-closure protein and the subunit 
of the mitochondrial receptor TOM40, can act as potential 
biomarkers and regulatory proteins in protector mechanisms 
that prevent AD (134).
11. Ginsenosides and individuals with Alzheimer's disease
The American National Institute of Neurological and 
Communication Disorders and Stroke, and the Alzheimer's 
Disease Association formed the most commonly used set 
of criteria for the diagnosis of AD. The following neuropsy-
chological tests are therefore widely used to assess cognitive 
impairment: i) Mini-Mental Status Examination (MMSE); 
ii) AD assessment scale (ADAS), which includes the cogni-
tive subscale (ADAS-cog) and the non-cognitive subscale 
(ADAS-non-cog); iii) ‘Frontal Assessment Battery’ (FAB) Test 
and iv) clinical dementia rating (CDR) (135).
Studies have been conducted to assess the effects of ginseng 
components on the course of AD in humans. The clinical 
efficacy of heat‑processed ginseng with the novel ginsenoside 
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complex, SG-135, was confirmed in relation to cognitive 
function in patients with moderately severe disease. An increase 
in the ADAS-cog, ADAS-non-cog and MMSE tests has been 
proven to occur as a function of the SG-135 dose (136).
The groups treated with the higher dose exhibited 
an improvement in cognitive improvement as early as at 
12 weeks, which was sustained for 24 weeks of follow-up. 
The SG-treated patients also exhibited an improving trend over 
time. Improvement in cognitive function following SG treat-
ment supports the findings that ginsenosides Rg3(R), Rg3(S) 
and Rg5/Rk1 exert memory-enhancing effects due to their 
neuroprotective actions against excitotoxicity (136).
Yang et al (137) investigated the neuroprotective and anti-
oxidant effects of ginsenoside compound K (CK) on a mouse 
model of memory impairment induced by scopolamine hydro-
bromide. It should be noted that protopanaxadiol saponin is 
degraded by the intestinal flora into ginsenoside CK (20‑O-β-D-
glucopyranosyl-20-(S)-protopanaxadiol) (CK). The role of CK 
in the regulation of Aβ and its ability to activate the Nrf2/
Keap1 signaling pathway have also been studied due to their 
great significance for AD. It has been proven that ginsen-
oside CK improves memory function, inhibits the expression 
of Aβ and activates the Nrf2/Keap1 signaling pathway in 
animals exposed to scopolamine. Based on these results, 
Yang et al (137) concluded that ginsenoside CK can improve 
memory function by regulating Aβ aggregation and facilitating 
the transduction of the Nrf2/Keap1 signaling pathway, thereby 
reducing oxidative damage to neurons and inhibiting neuronal 
apoptosis. Rg3 is the most effective ginsenoside having an 
Aβ-lowering effect, and the effect is correlated with the dose 
of Rg3. Similarly, Heo et al observed dose-related cognitive 
improvements following SG treatment (136).
Of note, Korean white ginseng root powder was previ-
ously shown to improve the performance of the ADAS-cog 
and MMSE tests. However, the ADAS-non-cog test scores 
remained unaltered, and the test scores evened out with those 
of the control group after the drug was discontinued (138). 
An increase in indicators was only found in the ADAS-cog 
and CDR tests, while the indicators of the ADAS-non-cog 
and MMSE tests were the same as those of the control group 
in a similar study using Korean red ginseng (KRG) root 
powder (139). Moreover, electroencephalography was used 
to assess the effectiveness of KRG root powder in relation to 
cognitive functions. An increase in relative alpha power was 
found in patients with AD who were treated with KRG root 
powder, which indicates an improvement in the functions of 
the frontal lobe. The FAB test scores also increased, although 
the MMSE scores remained unaltered (140).
In a different study, cognitive functions were assessed 
every 12 weeks, using the ADAS and the Korean version of 
the Mini-mental status examination (K-MMSE), to investigate 
maintenance doses of 4.5 and 9.0 g of KRG per day (141). A 
significant improvement was observed in groups that took 
KRG for 24 weeks. The improved MMSE score did not exhibit 
significant decreases at the 48th and 96th week, in a long‑term 
assessment of the impact effectiveness of KRG. Similar results 
were obtained in the ADAS-assessment. The maximum 
improvement was found on the 24th week (141).
In another study, improved cognitive function was 
demonstrated with KRG treatment as was the sustainability 
of the achieved clinical goals in patients with AD. Previously, 
data on the long-term effects of KRG in patients with AD 
were limited, and studies did not exceed a few months (138), 
meaning that these shorter-term studies did not exactly indi-
cate whether the effect of ginseng is temporary or whether it 
is able to continue to suppress the progressive course of AD. 
The results obtained in the long-term KRG study indicated 
that the effectiveness of KRG on cognitive function during 
the course of AD can be maintained for at least 2 years (141).
Several long-term (over 2 years) tests on AChE inhibi-
tors have demonstrated that, although the efficacy of the 
drugs is evident, they were not able to block or reverse 
cognitive decline (142,143). The 2-year MMSE decline typi-
cally ranged from 2.5 to 4.0 points compared to the initial 
estimate. The usual picture of cognitive decline shows an 
initial improvement of 3 or 6 months, and then decreases to 
baseline over about a year in patients taking conventional 
medication. The disease then progresses again. By contrast, 
the ADAS-cog and K-MMSE scores were stable and did not 
exhibit an obvious decrease at the registration times over 
2 years (141). This clinical picture can be explained by the 
difference in the main mechanisms of action of ginseng 
and anticholinesterase. The effect of ginseng on cognitive 
function with underlying specific mechanisms of influence 
has been considered (144). It is known that ginsenoside Rb1 
improves learning and memory in tasks that are dependent 
on the hippocampus, and that it increases cell survival in 
the dentate gyrus of the medial and lower hemispheres 
of the large brain and in the hippocampal subregion 
CA3 (145). Ginsenoside Rg1 has been observed to weaken 
Aβ1-42-induced neurotoxicity and τ-hyperphosphorylation, in 
a dose-dependent manner, at several sites that are associ-
ated with AD (146). Moreover, it has been suggested that 
ginsenoside Rg1 and Rb1 potentiate cholinergic pathways 
in the central nervous system and it was found that both 
ginsenosides Rg1 and Rb1 enhance the activity of ChAT and 
inhibit the activity of AChE, thereby enhancing the function 
of the cholinergic system (147).
The introduction of Rg1 and Rb1 to mice in the 
post-weaning period has been shown to increase the thick-
ness and density of the cerebral cortex in the CA3 region 
of the hippocampus, which is believed to modulate synaptic 
plasticity, regarded as one of the most important learning and 
memory mechanisms (148).
12. Conclusion
We herein present a literature survey on the ginseng compo-
nents that have exhibited biological activity on the pathogenesis 
of AD. Information on the effects of ginseng components on 
the signs of AD is depicted in Table III. The same symptoms 
that are observed in patients with AD are artificially created in 
animal models of AD; the mechanisms that trigger AD have 
not yet been confirmed with all possible accuracy. However, 
BAS found in ginseng can have a significant protective and 
inhibitory effect on the further development of AD, as shown 
by the foregoing review and general research data, summa-
rized in Table III. The data obtained in studies on the effects 
of ginseng components on patients with AD have shown that 
ginseng preparations can be used for maintenance therapy. 
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Table III. Effect of the components of ginseng on the pathogenesis of AD.
Model AD Treatment Research results Authors/(Refs.)
Enzyme activity Ginsenosides Rb1,  ↓ Activity AChE (except Rc); Shin et al (38)
measurement Rb2, Rc, Re,  ↓ Activity BChE (except Rc and Re);
(without models) Rg1 and Rg3 ↓ Activity BACE1 (except Rg3 and Re);
  Neutralization of pyroxynitrite;
  ↓ Nitrotyrosine formation;
Rat PC12 cells; Extract Panax japonicus 5 Components that are inhibitors of Li et al (37)
Introduction Aβ25-35  AChE were selected
Male ICR mice Cereboost™ (extract ↑ Cognitive abilities of mice; Li et al (103)
(6 weeks); Panax quinquefolius) ↓ Activity AChE;
Intracerebroventricular   ↓ Cytotoxicity Aβ1-42 in stem cell;
injection Aβ1-42  ↑ Expression ChAT;
  ↓ Level Aβ1-42;
  ↑ Level MAP2;
  ↑ Synaptophysin level;
  ↑ ACh level; 
Wistar rats Ginsenoside Rg5 ↑ Cognitive abilities of rats; Chu et al (41)
Streptozocin  ↑ Expression BDNF;
administration  ↑ Expression IGF-1;
  ↓ Level Aβ1-42;
  ↓ Activity AChE;
  ↑ Activity ChAT;
  ↓ Level TNF-α;
  ↓ Level IL‑1β;
  ↑ Expression COX-2;
  ↓ Expression NOS2; 
ICR male mice  White ginseng root extract Suppression of the activation of microglia; Choi et al (42)
(7 weeks, 30-33 g); (age 4 years) 
Intragypocampal  ↑ Memory function in mice;
injection AβO  ↓ Neuron death;
  ↑ Cholinergic degeneration 
  in the hippocampus 
N2a/APP695 cell line;  Ginsenoside Re ↓ Substance production Aβ; Cao et al (49)
  Activation PPARγ;
  ↓ Activity BACE1; 
Male Sprague-Dawley rats  Ginsenoside Rg1 ↑ Cognitive abilities of rats; Quan et al (50)
Intragypocampal   ↓ Level Aβ1-42;
injection Aβ1-42  ↑ Expression IDE;
  Activation PPARγ
Female rats with ovaries Ginsenoside Rd ↑ Cognitive abilities of rats; Yan et al (51)
removed (280-300 g)  ↓Level Aβ1-42;
HT22 hippocampal   ↑ Level sAPPα; 
neuronal cell line  ↑Activity of signalling pathway MAPK/ERK;
expressing ER  ↑ Activity of signalling pathway PI3K/AKT;
  ↑ Expression α-secretase;
  ↓ Expression BACE1;
  ↑ Level p-ERK, total level ERK was not altered;
  ↑ Level p-AKT, total level AKT was not altered;
  ↑ Expression p-ERα, total expression ERα,
  ERβ levels not altered;
Line of neuronal cells of  Ginsenoside Rg1 ↑ Cognitive abilities of rats; Shi et al (52)
the hippocampus HT22  ↑ Level sAPPα;
Human neuroblastoma cells  ↑ Activity α- secretase; 
SH-SY5Y
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Table III. Continued.
Model AD Treatment Research results Authors/(Refs.)
Female Wistar rats with   ↓ Level Aβ1-42; 
ovaries removed (9 months)   ↑ Level p-ERK and ERK;
  ↑ Level p-AKT and AKT;
  ↑ Expression p-ERα and ERα;
12 women with menopause  Ginsenoside Rg1 ↑ Level sAPPα; Shi et al (53)
Platelet rich plasma taken  ↓ Level Aβ1-42;
  ↑ Activity α- secretase;
  ↑ Level p-ERK1/2, without affecting 
  the overall level ERK1/2;
Female Wistar rats Ginsenoside Rg1 ↑ Cognitive abilities of rats; Zhang et al (54)
(10 weeks, 260-300 g)  ↓ Generation Aβ1-42;
Ovarian removal  ↓ Activity caspase-3;
Injection of D-galactose  ↓ Cell apoptosis;
  ↑ Expression ADAM10;
  ↓ Expression BACE1; 
Mice SAP8 (with elevated  Saponins from ↑ Activity α-secretase; Huang et al (55)
level APP and Aβ1-42)  Panax notoginseng ↓ Activity BACE1;
  Activity of γ-secretase was not altered 
Cortical neurons from  Ginsenoside Rh2 ↑ Cognitive abilities of mice; Qiu et al (58)
mouse embryos Tg2576  ↓ Level Aβ1-42;
  Activity of α-secretase and BACE1 
  was not altered;
  ↑ Level sAPPα;
  Total level of APP was not altered;
  ↑ Cholesterol level in neurons; 
Neuronal differentiated mouse Ginsenoside Rg3 ↓ Level Aβ1-42; Kang et al (64)
embryonic stem cells  ↑ Activity of PI4KIIα;
Transgenic APP/PSI mice
Human neuroblastoma Gintonin (glyco-lipoprotein ↑ Activity LPAR Hwang et al (89)
cells SH-SY5Y fraction of ginseng extract) ↓ Level Aβ1-42;
Transgenic mice (with   ↑ Level sAPPα;
elevated level Aβ1-42)  ↓ Cytotoxicity Aβ1-42 in cells;
  ↑ Cognitive abilities of mice;
  ↓ Microglial activation; 
Cell PC12 Ginsenoside Rg2 ↑ Cell viability; Cui et al (95)
Injection Aβ25-35  ↓ Level LDH;
  ↓ Level ROS;
  ↓ Intracellular level Ca2+;
  ↓ Activity of caspase-3;
  ↑ Ratio Bcl-2/Bax;
  ↑ Level p-Akt;
  ↓ Cytotoxicity Aβ1-42 in cells;
Cells PC12 Ginsenoside Rg2 ↑ Neuroprotective properties; Li et al (96)
Injection of glutamate  ↓ Intracellular level Ca2+;
  ↓ Level MDA;
  ↓ Level NO;
  ↓ Level Aβ1-42;
  ↓ Expression caspase-3;
  ↓ Expression calpain II; 
Primary cortical neurons Ginsenoside Rb1 ↓ Level p-tau; Chen et al (97)
Sprague-Dawley rats  ↓ Cytotoxicity Aβ25-35 in cells;
Injection Aβ25‑35  ↓ Level and expression CDK5;
  ↓ Calpain activity;
  ↓ Intracellular level Ca2+; 
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Table III. Continued.
Model AD Treatment Research results Authors/(Refs.)
SD rats Ginsenoside Rg1 ↓ Current density through high-threshold Quan et al (98)
Aβ25-35 injection  calcium channels through MAPK;
Female Wistar rats  Ginsenoside Rg1 ↓ Accumulation of NFTs; Mu et al (81)
(3 months),  ↓ Level of Aβ1-42; 
Tg APP/PSI rats  ↓ Apoptosis; 
  ↓ Expression of IRE-1;
  ↓ Expression of TRAF2;
  ↓ Expression of p-JNK;
Male Sprague-Dawley rats Ginsenoside Rd ↑ Cognitive abilities of rats; Liu et al (87)
Intragypocampal injection  ↑ Neuroprotective properties;
Aβ1-42 Liu J  ↓ Cytotoxicity of Aβ1-42;
  ↓ Expression IL‑1β;
  ↓ Level and expression of IL-6;
  ↑ Level and expression of IL-10;
  ↓ Level and expression of TNF-α;
  ↑ Expression of HSP70;
  ↓Ratio of GSSG/GSH;
  ↓ Expression of caspase-3; 
Primary cortical neurons Panax ginseng ↑ Survival rate  Li et al (103)
from the brain of C.A. Meyer ↓ Neuronal apoptosis in vitro;
newborn (0-24 h) mice; root extract ↑ Ratio of expression p-PKA/PKA 
 (aged 4 years) and p-CREB/CREB;
Female rats (260-280 g);  ↓ Concentration of MDA;
Injection of D-galactose  ↓ Concentration of NO;
and aluminum chloride  ↑ Ratio of Bcl-2/Bax;
  ↓ Expression of caspase-3;
  ↓ Level of p-Tau;
  ↑ Activity of SOD;
  ↓ Activity of NOS2 and NOS;
  ↑ Level of cAMP; 
Cortical cortical Radix Notoginseng  ↓ Cytotoxicity Aβ1-42 in cells; Choi et al (104)
neurons (PC12 cells) flavonol glycoside ↓ Level of Aβ1-42;
 (RNFG), quercetin  ↓ Level of ROS;
 3-O-β-D-xylo-
 pyranosyl‑β‑D‑
 galactopyranoside
APP transgenic mice Ginsenoside Rd ↑ Cognitive abilities of mice; Liu et al (88)
(10 months)  ↓ Expression and activity of NF-κB p65;
  ↓ Level of IL-1β;
  ↓ Level of TNF-α; d
  ↓ Level of IL-6;
  ↓ Level of IL-10; 
Male Wistar rats Ginsenoside Rb1 ↑ Cognitive abilities of rats; Wang et al (85)
(3-4 weeks, 250-300 g)  ↓ Level of Aβ1-42;0
Intracerebroventricular  ↓ Level of COX2;
injection Aβ1-42  ↑ Level of iNOS;
Female Wistar rats Panax ginseng C.A.  ↑ Cognitive abilities of rats; Li et al (114)
(260-280 g); Meyer root extract ↓ Quantity Aβ1-42;
Injection of D-galactose (age 4 years) ↓ Quantity p-tau;
and aluminum chloride  ↑ Activity of
  PI3K/Akt signalling pathway; 
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Table III. Continued.
Model AD Treatment Research results  Authors/(Refs.)
Male Sprague-Dawley rats Ginsenoside Rg1 ↓ Cognitive abilities of rats; Song et al (118=6)
(200-240 g)  ↓ Level of p-Tau;
Intracerebroventricular  ↑ Level of GSK3β-Tyr216;
injection OKA  ↑ Level of Aβ1-42;
Male Sprague-Dawley rats Ginsenoside Rd ↑ Cognitive abilities of mice; Zhang et al (119)
(270-320 g)  ↓ Level p-Tau;
Artificial cerebral ischemia  ↑ Activity of AKT
Male Sprague-Dawley rats Ginsenoside Rd ↑ Weight of rats without changing morphology Li et al (121)
  in the hippocampus and cerebral cortex;
Cortical neurons  ↑ Neuroprotective properties in vitro;
Injection OKA  ↓ Phosphorylation of Tau in vitro;
  ↑ Activity of PP-2A
APP/PSI mice  Ginsenoside Rg1 ↑ Memory function of mice; Li et al (75)
  ↓ Level p-Tau;
  ↓ Level of Aβ1-42;
  Expression of APP was not altered;
  ↓ Level of APP;
  ↑ Expression of BDNF;
  ↑ Level of p-TrkB; 
Male Wistar rats  Ginseng extract ↑ Cognitive abilities of mice; Zhang et al (43)
weighting 180-220 g    ↓ Neuronal death;
Injection of D-galactose (D-gal)  ↓ Level of Aβ1-42;
with AlCl3 (Al) for 60 days   ↓ Level of p-Tau;
  ↑ Blood glycine level;
  ↑ Level of 5- hydroxytryptamine in blood; 
Male SAMP8 and  Ginsenoside Rg1 ↑ Cognitive abilities of mice;  Shi et al (125)
SAMR1 mice (6 months)  ↓ Level of Aβ1-42;
  ↓ Level of PKA RIIα;
  ↑ Level of p-CREB;
  ↑ Level of BDNF 
12-Month-old mice (18-22 g); Ginsenoside Re ↑ Cognitive abilities of mice; Li et al (133)
  ↑ Hexadecanasphinganine and
  phytosphingosine concentrations;
Intracerebroventricular injection  ↑ Phenylalanine concentration;
  ↓ Tryptophan concentration
Male Kunming mice Ginsenosides Rg1 ↑ Level of LPC; Li et al (74)
(12-month-old mice, 18-22 g) and Rb1 ↓ Level of phenylalanine;
Intragypocampal   ↑ Tryptophan level;
injection Aβ1-42  ↑ Dihydrosphingosine for Rg1
  (unaltered level for Rb1)
Male mice APP/PSI Ginsenosides Rg1 ↑ Cognitive abilities of mice; Li et al (73)
and C57BL/6j and Rg2 ↓ Level Aβ1-42;
   ↑ Hypoxanthine level;
  ↑ Level LPC;
  Change in metabolic profile for sphingolipids
SH-SY5Y cells Ginsenoside Rb1 Change in levels of 40 proteins in response to Hwang et al (134)
Exposure to Aβ25-35 SILAC Rb1 pretreatment in β-amyloid-treated cells
40 Individuals with AD Ginsenoside  ↑ Indicators ADAS-cog; Heo et al (136)
(72.9 ± 9.4 years old) complex SG-135 ↑ Indicators ADAS-non-cog;
  ↑ Indicators K-MMSE
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At the same time, a drug that consists of correctly selected 
ratios of the various components of ginseng is likely to be 
more effective than a simple ginseng root extract. However, 
the creation of such a drug will entail large-scale studies on 
the effects of individual components of ginseng on patients 
with AD.
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97 Individuals with AD  Ginseng root powder ↑indicators MMSE; Lee et al (138)
(47-83 years old) (age 6 years) ↑indicators ADAS-cog;
  Indicators ADAS-non-cog did not change
  The MMSE and ADAS-cog rates 
  were the same as in the control group 
  12 weeks after discontinuation of the 
  ginseng drug 
61 Individuals with AD Red Korean Ginseng ↑ Indicators ADAS-cog; Heo et al (139)
(50-80 years old) root powder ↑ Indicators CDR;
  (age 6 years) Indicators ADAS-non-cog
  were not altered;
  Indicators MMSE
  were not altered 
14 Individuals with AD Red Korean ↑test results FAB; Heo et al (140)
(74.93±7.63 years old) Ginseng root powder ↑the power of the alpha rhythm
 (age 6 years) in the right temporal,
  parietal and occipital regions of the brain;
  K-MMSE did not change
61 Individuals with AD Red Korean Ginseng ↑indicators ADAS-cog; Heo et al (141)
(60-80 years old) root powder ↑indicators MMSE
 (age 6 years)
AD, Alzheimer’s disease; Ach, Acetylcholine; Ache, acetylcholinesterase; BChE, butyrylcholinesterase; APP, amyloid precursor 
protein; sAPPα, water soluble α-amyloid; ER, estrogen receptor; PI4KIIα, phosphatidylinositol-4-kinase 2α; LPC, lysophosphatidyl-
cholines; TrkB, tyrosine receptor kinase B; ADAM10, a-secretase a disintegrin and metallopeptidase domain 10; ROS, reactive oxygen 
species; TNF-α, tumour necrosis factor α; NO, nitric oxide; NOS2, synthase nitric oxide 2, induced; SD, Sprague-Dawley; CDK5, 
cyclin-dependent kinase 5; GSK3, glycogen synthase kinase 3; TRAF2; tumour necrosis factor receptor 2; p-JNK, phosphorylated-c-Jun 
N-terminal protein kinase associated with apoptosis; IGF-1, insulin-like growth factor-1; cAMP, cyclic adenosine monophosphate; CREB, 
cAMP response-element-binding protein; SILAC, stable isotope labelling of amino acids in a cell culture; MMSE, Mini-Mental Status 
Examination; K-MMSE Korean MMSE; CDR, Clinical Evaluation of Dementia; PPAR, peroxisome proliferator activated receptor.
MOLECULAR MEDICINE REPORTS  19:  2975-2998,  2019 2995
ence in terms of adjudicating on the final decision, for this 
article.
References
 1. Alzheimer A, Stelzmann RA, Schnitzlein HN and Murtagh FR: 
An English translation of Alzheimer’s 1907 paper, ‘Uber eine 
eigenartige Erkankung der Hirnrinde’. Clin Anat 8: 429-431, 1995.
 2. Hardy J and Allsop D: Amyloid deposition as the central event 
in the aetiology of Alzheimer’s disease. Trends Pharmacol 
Sci 12: 383-388, 1991.
 3. Donev R, Kolev M, Millet B and Thome J: Neuronal death in 
Alzheimer’s disease and therapeutic opportunities. J Cell Mol 
Med 13: 4329-4348, 2009.
 4. Liu Z, Li T, Li P, Wei N, Zhao Z, Liang H, Ji X, Chen W, 
Xue M and Wei J: The ambiguous relationship of oxidative 
stress, tau hyperphosphorylation, and autophagy dysfunction in 
Alzheimer’s disease. Oxid Med Cell Longev 2015: 352723, 2015.
 5. Hernández F and Avila J: Tauopathies. Cell Mol Life Sci 64: 
2219-2233, 2007.
 6. Brekhman II, Dardymov IV and Dobriakov II: On the pharma-
cology of individual glycosides from the roots of Panax ginseng 
C.A. Mey. Farmakol Toksikol 29: 167-171, 1966 (In Russian).
 7. Elyakov G, Strigina L, Khorlin A and Kochetkov H: Glycosides 
of ginseng (Panax ginseng C. A. Mey). Bulletin of the Academy 
of Sciences of The USSR, Division of Chemical Science. Vol 11, 
Issue 6, pp1055-1055, 1p, 1962. https://searchworks.stanford.
edu/articles/edb__72505988.
 8. Brekhman II: Ginseng. Government publisher of medicine 
literature. Medgiz, Saint Petersburg, pp 3-163, 1957 (Translated 
from Russian). http://moodle.pharmi.uz/library/books/Рус/
Қўшимча%20адабиётлар/Жень‑шень.pdf.
 9. Fischer FEL and Meyer CA: Enumeratio plantarum novarum 
a cl. Schrenk lectarum [Flora change from Cl. Schrenk 
Lectarum]. Petropoli Publishers, 1841-1842.
10. Arsenyev VK: Myths, legends, traditions, and fables of peoples 
of Far East. Monograph Series, International Institute of 
Ethnolinguistic and Oriental Studies (IIEOS), ISSN 1230-3283; 
10, ISBN 83-902273-4-7, 1995.
11. Przhevalsky N: Mongolia, The Tangut Country and the Solitudes 
of Northern Tibet. Translated by E.D. Morgan. Editor (Yule H). 
London: Sampson Low, Marston, Searle & Rivington, 2; 24, 1876.
12. Maak R: Journey through the Ussuri river valley. The Siberian 
Department of the Imperial Russian Geographical Society, 1-2. 
V. Bezobrazov and Co Printers, Saint Petersburg, 1861.
13. Maximowicz СJ: Diagnoses des nouvelles plantes du Japon 
et de la Mandjourie [Diagnoses of the new plants of Japan and 
Mandjourie]. In: Bulletin de l’Academie Imperiale des Sciences 
de St. Petersbourg. Tome dix-huitieme. Saint Petersbourg, XII 
decade, p 41.1873.
14. Komarov VL: Coniferae of Manchuria. Trudy Imp. Saint 
Petersburg. Obsc. 32: 230-241, 1902.
15. Shishkin IK: Studies about the flora of Iman River. Materials of 
the Vladivostok, Branch of the Russian Geographical Society 5: 
128-130, 1930.
16. Gutnikova ZI: Ginseng in Suputinsky reserve. Materials of the 
Academy of Sciences of the USSR 4: 257-267, 1941.
17. Gutnikova ZI: Preliminary data on the culture of ginseng in the 
conditions of Suputinsky reserve. Materials of the Academy of 
Sciences of the USSR 1955.
18. Vysotsky KK: To the question of the biology of wild ginseng. 
Main Directorate of USSR Reserves 7: 254-262, 1940.
19. Bayanova VB: Conditions of ginseng growth in the ‘Kedrovaya 
Pad’ reserve. Materials of the mountain taiga station of the 
Academy of Sciences of the USSR 4: 217-231, 1941.
20. Kurentsova GE: Medicinal plants of the Soviet Far East. Materials 
of the mountain taiga station of the Academy of Sciences of the 
USSR 4: 15-97, 1941.
21. Zakutinsky DI: Pharmacology of ginseng root. Pharmacol 
Toxicol 7: 13-16, 1944.
22. Burkat ME and Saksonov P: Materials for the pharmacological 
characterization of ginseng root. Pharmacol Toxicol 10: 7-16, 1947.
23. Kiselev VS: Pharmacological study of the ginseng root. Pharmacol 
Toxicol 11: 50-57, 1948.
24. Shapiro ML: Ginseng is an active therapeutic drug. J Sov Med 6: 
17-19, 1947.
25. Kuzminskaya RA: Treatment of vegetative dystonia with ginseng 
root. Neuropathol Psych 2: 62-63, 1949.
26. Buturlin VV: The use of ginseng root in clinical practice. Sov 
Med 5: 34-36, 1950.
27. Brekhman II and Dardymov IV: Pharmacological investigation 
of glycosides from ginseng and eleutherococcus. Lloydia 32: 
46-51, 1969.
28. Elyakov GB, Strigina LI, Uvarova NI, Vaskovsky VE, 
Dzizenko AK and Kochetkov NK: Glycosides from ginseng 
roots. Tetrahedron Lett 5: 3591-3597, 1964.
29. Elyakov GB, Strigina LI and Kochetkov NK: Glycosides 
from ginseng roots. VI. Structure of the carbohydrate chain of 
panaxoside A. In: Chemistry of Natural Compounds. Vol. 1, 
Issue 3, pp114-116, 1965.
30. Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, Lehmann J and 
Zhang Y: Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids 
as potent, multifunctional acetyl- and butyrylcholinesterase 
inhibitors. J Med Chem 55: 4309-4321, 2012.
31. Geula C and Mesulam MM: Cholinesterases and the pathology 
of Alzheimer disease. Alzheimer Dis Assoc Disord 9 (Suppl 2): 
23-28, 1995.
32. Wilkinson DG, Francis PT, Schwam E and Payne-Parrish J: 
Cholinesterase inhibitors used in the treatment of Alzheimer’s 
disease: The relationship between pharmacological effects and 
clinical efficacy. Drugs Aging: 21, 453‑478, 2004. 
33. Raschetti R, Albanese E, Vanacore N and Maggini M: 
Cholinesterase inhibitors in mild cognitive impairment: A 
systematic review of randomised trials. PLoS Med 4: e338, 2007.
34. Collins LE, Paul NE, Abbas SF, Leser CE, Podurgiel SJ, 
Galtieri DJ, Chrobak JJ, Baqi Y, Müller CE and Salamone JD: Oral 
tremor induced by galantamine in rats: A model of the parkin-
sonian side effects of cholinomimetics used to treat Alzheimer’s 
disease. Pharmacol Biochem Behav 99: 414-422, 2011.
35. Ikonomovic MD, Mufson EJ, Wuu J, Bennett DA and 
DeKosky ST: Reduction of choline acetyltransferase activity in 
primary visual cortex in mild to moderate Alzheimer’s disease. 
Arch Neurol 62: 425-430, 2005.
36. Choi RJ, Roy A, Jung HJ, Ali MY, Min BS, Park CH, 
Yokozawa T, Fan TP, Choi JS and Jung HA: BACE1 molecular 
docking and anti-Alzheimer’s disease activities of ginsenosides. 
J Ethnopharmacol 190: 219-230, 2016.
37. Li S, Liu C, Liu C and Zhang Y: Extraction and in vitro screening 
of potential acetylcholinesterase inhibitors from the leaves of 
Panax japonicus. J Chromatogr B Analyt Technol Biomed Life 
Sci 1061-1062: 139-145, 2017.
38. Shin K, Guo H, Cha Y, Ban YH, Seo W, Choi Y, Kim TS, Lee SP, 
Kim JC, Choi EK, et al: Cereboost™, an American ginseng 
extract, improves cognitive function via up-regulation of choline 
acetyltransferase expression and neuroprotection. Regul Toxicol 
Pharmacol 78: 53-58, 2016.
39. Lee MR, Yun BS, Liu L, Zhang DL, Wang Z, Wang CL, Gu LJ, 
Wang CY, Mo EK and Sung CK: Effect of black ginseng 
on memory improvement in the amnesic mice induced by 
scopolamine. J Ginseng Res 34: 51-58, 2010.
40. Wang Q, Sun LH, Jia W, Liu XM, Dang HX, Mai WL, Wang N, 
Steinmetz A, Wang YQ and Xu CJ: Comparison of ginsenosides 
Rg1 and Rb1 for their effects on improving scopolamine-induced 
learning and memory impairment in mice. Phytother Res 24: 
1748-1754, 2010.
41. Chu S, Gu J, Feng L, Liu J, Zhang M, Jia X, Liu M and Yao D: 
Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid 
deposition in STZ-induced memory impaired rats via attenuating 
neuroinflammatory responses. Int Immunopharmacol 19: 
317-326, 2014.
42. Choi JG, Kim N, Huh E, Lee H, Oh MH, Park JD, Pyo MK and 
Oh MS: White ginseng protects mouse hippocampal cells against 
amyloid-beta oligomer toxicity. Phytother Res 31: 497-506, 2017.
43. Zhang Y, Pi Z, Song F and Liu Z: Ginsenosides attenuate 
d-galactose- and AlCl3-induced spatial memory impairment 
by restoring the dysfunction of the neurotransmitter systems in 
the rat model of Alzheimer’s disease. J Ethnopharmacol 194: 
188-195, 2016.
44. Karp G (ed): Cell and Molecular Biology: Concepts and 
Experiments. 6th edition. John Wiley & Sons, New York, NY, 
2009.
45. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, 
Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al: 
Beta-secretase cleavage of Alzheimer’s amyloid precursor protein 
by the transmembrane aspartic protease BACE. Science 286: 
735-741,1999.
46. Ohnishi S and Takano K: Amyloid fibrils from the viewpoint of 
protein folding. Cell Mol Life Sci 61: 511-524, 2004.
RAZGONOVA et al:  Panax ginseng COMPONENTS AND ALZHEIMER'S DISEASE2996
47. Fahrenholz F: Alpha-secretase as a therapeutic target. Curr 
Alzheimer Res 4: 412-417, 2007.
48. Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, 
Tsarouhas K, Ilie M, Tsatsakis AM and Kouretas D: Alzheimer’s 
disease treated patients showed different patterns for oxidative 
stress and inflammation markers. Food Chem Toxicol 61: 
209-214, 2013.
49. Cao G, Su P, Zhang S, Guo L, Zhang H, Liang Y, Qin C and 
Zhang W: Ginsenoside Re reduces Aβ production by acti-
vating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J 
Pharmacol 793: 101-108, 2016.
50. Quan Q, Wang J, Li X and Wang Y: Ginsenoside Rg1 decreases 
Aβ1-42 level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer’s disease. PLoS One 8: 
e59155, 2013.
51. Yan X, Hu G, Yan W, Chen T, Yang F, Zhang X, Zhao G and 
Liu J: Ginsenoside Rd promotes non-amyloidogenic pathway of 
amyloid precursor protein processing by regulating phosphory-
lation of estrogen receptor alpha. Life Sci 168: 16-23, 2017.
52. Shi C, Zheng DD, Fang L, Wu F, Kwong WH, and Xu J: 
Ginsenoside Rg1 promotes nonamyloidogenic cleavage of APP 
via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. 
Biochim Biophys Acta 1820: 453-460, 2012.
53. Shi C, Na N, Zhu X and Xu J: Estrogenic effect of ginsenoside 
Rg1 on APP processing in post-menopausal platelets. Platelets 24: 
51-62, 2013.
54. Zhang X, Wang J, Xing Y, Gong L, Li H, Wu Z, Li Y, Wang J, 
Wang Y, Dong L and Li S: Effects of ginsenoside Rg1 or 
17β-estradiol on a cognitively impaired, ovariectomized rat 
model of Alzheimer’s disease. Neuroscience 220: 191-200, 
2012.
55. Huang J, Wu D, Wang J, Li F, Lu L, Gao Y and Zhong Z: 
Effects of Panax notoginseng saponin on α, β, and γ secretase 
involved in Aβ deposition in SAMP8 mice. Neuroreport 25: 
89-93, 2014.
56. Zetterberg H, Alexander DM, Spandidos DA and Blennow K: 
Additional evidence for antagonistic pleiotropic effects of APOE. 
Alzheimers Dement 5: 75, 2009.
57. Endres K and Fahrenholz F: Upregulation of the α-secretase 
ADAM10-risk or reason for hope? FEBS J 277: 1585-1596, 
2010.
58. Qiu J, Li W, Feng SH, Wang M and He ZY: Ginsenoside Rh2 
promotes nonamyloidgenic cleavage of amyloid precursor 
protein via a cholesterol-dependent pathway. Genet Mol Res 13: 
3586-3598, 2014.
59. Reiss AB and Voloshyna I: Regulation of cerebral cholesterol 
metabolism in Alzheimer disease. J Investig Med 60: 576-582, 
2012.
60. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, 
Hadziselimovic A, Beel AJ and Sanders CR: The amyloid 
precursor protein has a flexible transmembrane domain and 
binds cholesterol. Science 336: 1168-1171, 2012.
61. Korade Z and Kenworthy AK: Lipid rafts, cholesterol, and the 
brain. Neuropharmacology 55: 1265-1273, 2008.
62. Di Paolo G and De Camilli P: Phosphoinositides in cell regu-
lation and membrane dynamics. Nature 443: 651-657, 2006.
63. Balla A and Balla T: Phosphatidylinositol 4-kinases: Old enzymes 
with emerging functions. Trends Cell Biol 16: 351-361, 2006.
64. Kang MS, Baek SH, Chun YS, Moore AZ, Landman N, 
Berman D, Hyun Ok Yang, Morishima-Kawashima M, Osawa S, 
Funamoto S, et al: Modulation of lipid kinase PI4KIIα activity and 
lipid raft association of presenilin 1 underlies γ-secretase inhi-
bition by ginsenoside (20S) Rg3. J Biol Chem 288: 20868-20882, 
2013.
65. Kwik J, Boyle S, Fooksman D, Margolis L, Sheetz MP and 
Edidin M: Membrane cholesterol, lateral mobility, and the phos-
phatidylinositol 4,5-bisphosphate-dependent organization of cell 
actin. Proc Natl Acad Sci USA 100: 13964-13969, 2003.
66. Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, 
Ostaszewski BL, van Dorsselaer A, Wang R, Selkoe DJ and Wolfe 
MS: Purification and characterization of the human γ-secretase 
complex. Biochemistry 43: 9774-9789, 2004.
67. Barber J: Merck & Co. terminates Phase III study of verubecestat 
in prodromal Alzheimer’s disease. First Word Farma, Feb 13, 
2018. https://www.firstwordpharma.com/node/1542930.
68. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, 
Kieburtz K, He F, Sun X, Thomas RG, et al; Alzheimer’s 
Disease Cooperative Study Steering Committee; Semagacestat 
Study Group: A phase 3 trial of semagacestat for treatment of 
Alzheimer’s disease. N Engl J Med 369: 341-350, 2013.
69. Yang L, Hao J, Zhang J, Xia W, Dong X, Hu X, Kong F and Cui X: 
Ginsenoside Rg3 promotes beta-amyloid peptide degradation by 
enhancing gene expression of neprilysin. J Pharm Pharmacol 61: 
375-380, 2009.
70. He Y, Zhao H and Su G: Ginsenoside Rg1 decreases neurofi-
brillary tangles accumulation in retina by regulating activities 
of neprilysin and PKA in retinal cells of AD mice model. J Mol 
Neurosci 52: 101-106, 2014.
71. Tohda C, Matsumoto N, Zou K, Meselhy MR and Komatsu K: 
Abeta(25-35)-induced memory impairment, axonal atrophy, 
and synaptic loss are ameliorated by M1, A metabolite of 
protopanaxadiol-type saponins. Neuropsychopharmacology 29: 
860-868, 2004.
72. Androutsopoulos VP, Kanavouras K and Tsatsakis AM: Role 
of paraoxonase 1 (PON1) in organophosphate metabolism: 
Implications in neurodegenerative diseases. Toxicol Appl 
Pharmacol 256: 418-424, 2011.
73. Li N, Liu Y, Li W, Zhou L, Li Q, Wang X and He P: A 
UPLC/MS-based metabolomics investigation of the protective 
effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer’s 
disease. J Ginseng Res 40: 9-17, 2016.
74. Li N, Zhou L, Li W, Liu Y, Wang J and He P: Protective effects 
of ginsenosides Rg1 and Rb1 on an Alzheimer’s disease mouse 
model: A metabolomics study. J Chromatogr B Analyt Technol 
Biomed Life Sci 985: 54-61, 2015.
75. Li F, Wu X, Li J and Niu Q: Ginsenoside Rg1 ameliorates hippo-
campal long-term potentiation and memory in an Alzheimer’s 
disease model. Mol Med Rep 13: 4904-4910, 2016.
76. Li X, Liu Y, Zhang X, Yuan H and Quan Q: [Effect of 
ginsenoside Rg1 on expressions of phosphory protein tau and 
N-methyl-D-aspartate receptor subunits NR1 and NR2B in rat 
brain slice model of Alzheimer’s disease]. Zhongguo Zhong Yao 
Za Zhi 35: 3339-3343, 2010 (In Chinese).
77. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, 
Hamto P, Devidze N, Yu GQ, et al: Amyloid-β/Fyn-induced 
synaptic, network, and cognitive impairments depend on tau levels 
in multiple mouse models of Alzheimer’s disease. J Neurosci 31: 
700-711, 2011.
78. Broestl L, Worden K, Moreno AJ, Davis EJ, Wang D, Garay B, 
Singh T, Verret L, Palop JJ and Dubal DB: Ovarian Cycle Stages 
Modulate Alzheimer-Related Cognitive and Brain Network 
Alterations in Female Mice. eNeuro 5: pii: ENEURO.0132-17.2018, 
2018.
79. Yang JT, Wang ZJ, Cai HY, Yuan L, Hu MM, Wu MN and Qi JS: 
Sex Differences in Neuropathology and Cognitive Behavior in 
APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer’s 
Disease. Neurosci Bull 34: 736-746, 2018.
80. Wang Y, Kan H, Yin Y, Wu W, Hu W, Wang M, Li W and 
Li W: Protective effects of ginsenoside Rg1 on chronic restraint 
stress induced learning and memory impairments in male mice. 
Pharmacol Biochem Behav 120: 73-81, 2014.
81. Mu JS, Lin H, Ye JX, Lin M and Cui XP: Rg1 exhibits neuroprotective 
effects by inhibiting the endoplasmic reticulum stress-mediated 
c-Jun N-terminal protein kinase apoptotic pathway in a rat model of 
Alzheimer’s disease. Mol Med Rep 12: 3862-3868, 2015.
82. Wang ZJ, Sun L, Peng W, Ma S, Zhu C, Fu F and Heinbockel T: 
Ginseng derivative ocotillol enhances neuronal activity through 
increased glutamate release: A possible mechanism underlying 
increased spontaneous locomotor activity of mice. Neuroscience 
195: 1-8, 2011.
83. Wang C-M, Liu M-Y, Wang F, Wei MJ, Wang S, Wu CF and 
Yang JY: Anti-amnesic effect of pseudoginsenoside-F11 in two 
mouse models of Alzheimer’s disease. Pharmacol Biochem 
Behav 106: 57-67, 2013.
84. Yan S, Li Z, Li H, Arancio O and Zhang W: Notoginsenoside 
R1 increases neuronal excitability and ameliorates synaptic and 
memory dysfunction following amyloid elevation. Sci Rep 4: 6352, 
2014.
85. Wang Y, Liu J, Zhang Z, Bi P, Qi Z and Zhang C: Anti neuroin-
flammation effect of ginsenoside Rbl in a rat model of Alzheimer 
disease. Neurosci Let 487: 70-72, 2011.
86. Lv C, Li Q, Zhang Y, Sui Z, He B, Xu H, Yin Y, Chen X and 
Bi K: A UFLC-MS/MS method with a switching ionization 
mode for simultaneous quantitation of polygalaxanthone III, four 
ginsenosides and tumulosic acid in rat plasma: Application to a 
comparative pharmacokinetic study in normal and Alzheimer’s 
disease rats. J Mass Spectrom 48: 904-913, 2013.
87. Liu J, Yan X, Li L, Zhu Y, Qin K, Zhou L, Sun D, Zhang X, Ye R 
and Zhao G: Ginsennoside rd attenuates cognitive dysfunction in a 
rat model of Alzheimer’s disease. Neurochem Res 37: 2738-2747, 
2012.
MOLECULAR MEDICINE REPORTS  19:  2975-2998,  2019 2997
 88. Liu J, Yan X, Li L, Li Y, Zhou L, Zhang X, Hu X and Zhao G: 
Gingenoside Rd Improves Learning and Memory Ability in 
APP Transgenic Mice. J Mol Neurosci 57: 522-528, 2015.
 89. Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, Kang J, Kim HJ, 
Kwon SH, Jang CG, Lee JH, et al: Gintonin, a ginseng-derived 
lysophosphatidic acid receptor ligand, attenuates Alzheimer’s 
disease-related neuropathies: Involvement of non-amyloidogenic 
processing. J Alzheimers Dis 31: 207-223, 2012.
 90. Choi DW and Rothman SM: The role of glutamate neuro-
toxicity in hypoxic-ischemic neuronal death. Annu Rev 
Neurosci 13: 171-182, 1990.
 91. Braughler JM and Hall ED: Central nervous system trauma 
and stroke. I. Biochemical considerations for oxygen radical 
formation and lipid peroxidation. Free Radic Biol Med 6: 
289-301, 1989.
 92. Sousa SC, Maciel EN, Vercesi AE and Castilho RF: Ca2+-induced 
oxidative stress in brain mitochondria treated with the respi-
ratory chain inhibitor rotenone. FEBS Lett 543: 179-183, 2003.
 93. Dante S, Hauss T and Dencher NA: β-amyloid 25 to 35 is inter-
calated in anionic and zwitterionic lipid membranes to different 
extents. Biophys J 83: 2610-2616, 2002.
 94. Ekinci FJ, Malik KU and Shea TB: Activation of the 
L voltage-sensitive calcium channel by mitogen-activated 
protein (MAP) kinase following exposure of neuronal cells to 
β-amyloid. MAP kinase mediates β-amyloid-induced neurode-
generation. J Biol Chem 274: 30322-30327, 1999.
 95. Cui J, Wang J, Zheng M, Gou D, Liu C and Zhou Y: Ginsenoside Rg2 
protects PC12 cells against β-amyloid25-35-induced apoptosis 
via the phosphoinositide 3-kinase/Akt pathway. Chem Biol 
Interact 275: 152-161, 2017.
 96. Li N, Liu B, Dluzen DE and Jin Y: Protective effects of 
ginsenoside Rg2 against glutamate-induced neurotoxicity in 
PC12 cells. J Ethnopharmacol 111: 458-463, 2007.
 97. Chen X, Huang T, Zhang J, Song J, Chen L and Zhu Y: Involvement 
of calpain and p25 of CDK5 pathway in ginsenoside Rb1’s 
attenuation of β-amyloid peptide25-35-induced tau hyperphos-
phorylation in cortical neurons. Brain Res 1200: 99-106, 2008.
 98. Quan QK, Li X, Yuan HF, Wang Y and Liu WL: Ginsenoside 
Rg1 inhibits high-voltage-activated calcium channel currents in 
hippocampal neurons of beta-amyloid peptide-exposed rat brain 
slices. Chin J Integr Med: Jan 15, 2016. (Epub ahead of print)
 99. Kim S and Rhim H: Ginsenosides inhibit NMDA 
receptor-mediated epileptic discharges in cultured hippocampal 
neurons. Arch Pharm Res 27: 524-530, 2004.
100. Shin E-J, Koh YH, Kim A-Y, Nah SY, Jeong JH, Chae JS, 
Kim SC, Yen TP, Yoon HJ and Kim WK: Ginsenosides 
attenuate kainic acid-induced synaptosomal oxidative stress via 
stimulation of adenosine A(2A) receptors in rat hippocampus. 
Behav Brain Res 197: 239-245, 2009.
101. Blomgren K, Zhu C, Wang X, Karlsson JO, Leverin AL, Bahr BA, 
Mallard C and Hagberg H: Synergistic activation of caspase-3 
by m-calpain after neonatal hypoxia-ischemia-a mechanism of 
pathological apoptosis. J Biol Chem 276: 10191-10198, 2001.
102. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, 
Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, et al: 
Involvement of caspases in proteolytic cleavage of Alzheimer’s 
amyloid-β precursor protein and amyloidogenic A β peptide 
formation. Cell 97: 395-406, 1999.
103. Li H, Song J, Zhang J, Wang T, Yan Y, Tao Z, Li S, Zhang H, 
Kang T and Yang J: Ginseng protein reverses amyloid beta 
peptide and H2O2 cytotoxicity in neurons, and ameliorates cognitive impairment in AD rats induced by a combination of 
D-galactose and AlCl3. Phytother Res 31: 284-295, 2017.
104. Choi RCY, Zhu JT, Leung KW, Chu GK, Xie HQ, Chen VP, 
Zheng KY, Lau DT, Dong TT, Chow PC, et al: A flavonol 
glycoside, isolated from roots of Panax notoginseng, reduces 
amyloid-β-induced neurotoxicity in cultured neurons: Signaling 
transduction and drug development for Alzheimer’s disease. J 
Alzheimers Dis 19: 795-811, 2010.
105. May MJ and Ghosh S: IkappaB kinases: Kinsmen with different 
crafts. Science 284: 271-273, 1999.
106. Boissière F, Hunot S, Faucheux B, Duyckaerts C, Hauw JJ, 
Agid Y and Hirsch EC: Nuclear translocation of NF-kappaB 
in cholinergic neurons of patients with Alzheimer’s disease. 
Neuroreport 8: 2849-2852, 1997.
107. Park EK, Shin YW, Lee HU, Kim SS, Lee YC, Lee BY and 
Kim DH: Inhibitory effect of ginsenoside Rb1 and compound K on 
NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced 
by lipopolysaccharide. Biol Pharm Bull 28: 652-656, 2005.
108. Kim SF, Huri DA and Snyder SH: Inducible nitric oxide synthase 
binds, S-nitrosylates, and activates cyclooxygenase-2. Science 
310: 1966-1970, 2005.
109. Prast H and Philippu A: Nitric oxide as modulator of neuronal 
function. Prog Neurobiol 64: 51-68, 2001.
110. Li Y, Zhao Y, Li G, Wang J, Li T, Li W and Lu J: Regulation 
of neuronal nitric oxide synthase exon 1f gene expression by 
nuclear factor-kappaB acetylation in human neuroblastoma 
cells. J Neurochem 101: 1194-1204, 2007.
111. Kashour T, Burton T, Dibrov A and Amara FM: Late 
Simian virus 40 transcription factor is a target of the phos-
phoinositide 3-kinase/Akt pathway in anti-apoptotic Alzheimer’s 
amyloid precursor protein signalling. Biochem J 370: 1063-1075, 
2003.
112. van der Heide LP, Ramakers GMJ and Smidt MP: Insulin 
signaling in the central nervous system: Learning to survive. 
Prog Neurobiol 79: 205-221, 2006.
113. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, 
Jones PK, Ghanbari H, Wataya T, Shimohama S, et al: Oxidative 
damage is the earliest event in Alzheimer disease. J Neuropathol 
Exp Neurol 60: 759-767, 2001.
114. Li H, Kang T, Qi B, Kong L, Jiao Y, Cao Y, Zhang J and Yang J: 
Neuroprotective effects of ginseng protein on PI3K/Akt signaling 
pathway in the hippocampus of D-galactose/AlCl3 inducing rats 
model of Alzheimer’s disease. J Ethnopharmacol 179: 162-169, 
2016.
115. Kanemaru K: Immunotherapy targeting misfolded proteins 
in neurodegenerative disease. Brain Nerv 65: 469-474, 
2013 (In Japanese).
116. Song XY, Hu JF, Chu SF, Zhang Z, Xu S, Yuan YH, Han N, 
Liu Y, Niu F, He X and Chen NH: Ginsenoside Rg1 attenuates 
okadaic acid induced spatial memory impairment by the 
GSK3β/tau signaling pathway and the Aβ formation prevention 
in rats. Eur J Pharmacol 710: 29-38, 2013.
117. Plattner F, Angelo M and Giese KP: The roles of cyclin-dependent 
kinase 5 and glycogen synthase kinase 3 in tau hyperphosphory-
lation. J Biol Chem 281: 25457-25465, 2006.
118. Li L, Liu Z, Liu J, Tai X, Hu X, Liu X, Wu Z, Zhang G, Shi M and 
Zhao G: Ginsenoside Rd attenuates beta-amyloid-induced tau 
phosphorylation by altering the functional balance of glycogen 
synthase kinase 3beta and protein phosphatase 2A. Neurobiol 
Dis 54: 320-328, 2013.
119. Zhang X, Shi M, Ye R, Wang W, Liu X, Zhang G, Han J, Zhang Y, 
Wang B, Zhao J, et al: Ginsenoside Rd attenuates tau protein 
phosphorylation via the PI3K/AKT/GSK-3β pathway after 
transient forebrain ischemia. Neurochem Res 39: 1363-1373, 
2014.
120. Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K 
and Gong CX: Reduced O-GlcNAcylation links lower brain 
glucose metabolism and tau pathology in Alzheimer’s disease. 
Brain 132: 1820-1832, 2009.
121. Li L, Liu J, Yan X, Qin K, Shi M, Lin T, Zhu Y, Kang T 
and Zhao G: Protective effects of ginsenoside Rd against 
okadaic acid-induced neurotoxicity in vivo and in vitro. J 
Ethnopharmacol 138: 135-141, 2011.
122. Xu B, Gottschalk W, Chow A, Wilson RI, Schnell E, Zang K, 
Wang D, Nicoll RA, Lu B and Reichardt LF: The role of 
brain-derived neurotrophic factor receptors in the mature 
hippocampus: Modulation of long-term potentiation through 
a presynaptic mechanism involving TrkB. J Neurosci 20: 
6888-6897, 2000.
123. Sakata K, Mastin JR, Duke SM, Vail MG, Overacre AE, 
Dong BE and Jha S: Effects of antidepressant treatment on mice 
lacking brain-derived neurotrophic factor expression through 
promoter IV. Eur J Neurosci 37: 1863-1874, 2013.
124. West AE, Chen WG, Dalva MB, Dolmetsch RE, Kornhauser  JM, 
Shaywitz AJ, Takasu MA, Tao X and Greenberg ME: Calcium 
regulation of neuronal gene expression. Proc Natl Acad Sci 
USA 98: 11024-11031, 2001.
125. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, Zhu YG 
and Chen XC: Ginsenoside Rg1 attenuates amyloid-β content, 
regulates PKA/CREB activity, and improves cognitive 
performance in SAMP8 mice. J Alzheimers Dis 19: 977-989, 
2010.
126. Bao C, Wang Y, Min H, Zhang M, Du X, Han R and Liu X: 
Combination of ginsenoside Rg1 and bone marrow mesen-
chymal stem cell transplantation in the treatment of cerebral 
ischemia reperfusion injury in rats. Cell Physiol Biochem 37: 
901-910, 2015.
RAZGONOVA et al:  Panax ginseng COMPONENTS AND ALZHEIMER'S DISEASE2998
127. Zhou Y, Li HQ, Lu L, Fu DL, Liu AJ, Li JH and Zheng GQ: 
Ginsenoside Rg1 provides neuroprotection against blood 
brain barrier disruption and neurological injury in a rat model 
of cerebral ischemia/reperfusion through downregulation of 
aquaporin 4 expression. Phytomedicine 21: 998-1003, 2014.
128. Li Y, Guan Y, Wang Y, Yu CL, Zhai FG and Guan LX: 
Neuroprotective effect of the ginsenoside Rg1 on cerebral 
ischemic injury in vivo and in vitro is mediated by PPARγ-
regulated antioxidative and anti‑inflammatory pathways. Evid 
Based Complement Alternat Med 2017: 7842082, 2017. doi: 
10.1155/2017/7842082.
129. Yang Y, Li X, Zhang L, Liu L, Jing G and Cai H: Ginsenoside Rg1 
suppressed inflammation and neuron apoptosis by activating 
PPARγ/HO-1 in hippocampus in rat model of cerebral 
ischemia-reperfusion injury. Int J Clin Exp Pathol 8: 2484-2494, 
2015.
130. Lin M, Sun W, Gong W, Ding Y, Zhuang Y and Hou Q: 
Ginsenoside Rg1 protects against transient focal cerebral 
ischemic injury and suppresses its systemic metabolic changes 
in cerebral injury rats. Acta Pharmaceutica Sinica B 5: 277-284, 
2015.
131. Xie CL, Li JH, Wang WW, Zheng GQ and Wang LX: Neuroprotective 
effect of ginsenoside-Rg1 on cerebral ischemia/reperfusion injury 
in rats by downregulating protease-activated receptor-1 expression. 
Life Sci 121: 145-151, 2015.
132. Sun C, Lai X, Huang X and Zeng Y: Protective effects of 
ginsenoside Rg1 on astrocytes and cerebral ischemic-reperfusion 
mice. Biol Pharm Bull 37: 1891-1898, 2014.
133. Li J, Liu Y, Li W, Wang Z, Guo P, Li L and Li N: Metabolic 
profiling of the effects of ginsenoside Re in an Alzheimer’s 
disease mouse model. Behav Brain Res 337: 160-172, 2018.
134. Hwang JY, Shim JS, Song MY, Yim SV, Lee SE and Park KS: 
Proteomic analysis reveals that the protective effects of ginsenoside 
Rb1 are associated with the actin cytoskeleton in β-amyloid-treated 
neuronal cells. J Ginseng Res 40: 278-284, 2016.
135. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-
Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, 
Jicha G, et al: Research criteria for the diagnosis of Alzheimer’s 
disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 
734-746, 2007.
136. Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY and Kim M: 
Heat-processed ginseng enhances the cognitive function in 
patients with moderately severe Alzheimer’s disease. Nutr 
Neurosci 15: 278-282, 2012.
137. Yang Q, Lin J, Zhang H, Liu Y, Kan M, Xiu Z, Chen X, Lan X, 
Shi X, Li N and Qu X: Ginsenoside compound K regulates 
amyloid β via the Nrf2/Keap1 signalling pathway in mice with 
scopolamine hydrobromide-induced memory impairments. J 
Mol Neurosci 67: 62-71, 2019.
138. Lee ST, Chu K, Sim JY, Heo JH and Kim M: Panax ginseng 
enhances cognitive performance in Alzheimer disease. 
Alzheimer Dis Assoc Disord 22: 222-226, 2008.
139. Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY and Kim M: 
An open-label trial of Korean red ginseng as an adjuvant 
treatment for cognitive impairment in patients with Alzheimer’s 
disease. Eur J Neurol 15: 865-868, 2008.
140. Heo JH, Park MH and Lee JH: Effect of Korean red ginseng 
on cognitive function and quantitative EEG in patients with 
Alzheimer’s disease: A preliminary study. J Altern Complement 
Med 22: 280-285, 2016.
141. Heo JH, Lee ST, Oh MJ, Park HJ, Shim JY, Chu K and Kim M: 
Improvement of cognitive deficit in Alzheimer’s disease patients 
by long term treatment with korean red ginseng. J Ginseng 
Res 35: 457-461, 2011.
142. Burns A, Gauthier S and Perdomo C: Efficacy and safety of 
donepezil over 3 years: An open-label, multicentre study in 
patients with Alzheimer’s disease. Int J Geriatr Psychiatry 22: 
806-812, 2007.
143. Minthon L, Wallin AK, Eriksson S, Wattmo C and Andreasen N: 
Long-term rivastigmine treatment in a routine clinical setting. 
Acta Neurol Scand 119: 180-185, 2009.
144. Scholey A, Ossoukhova A, Owen L, Ibarra A, Pipingas A, 
He K, Roller M and Stough C: Effects of American ginseng 
(Panax quinquefolius) on neurocognitive function: An acute, 
randomised, double-blind, placebo-controlled, crossover study. 
Psychopharmacology (Berl) 212: 345-356, 2010.
145. Liu L, Hoang-Gia T, Wu H, Lee MR, Gu L, Wang C, Yun BS, 
Wang Q, Ye S and Sung CK: Ginsenoside Rb1 improves spatial 
learning and memory by regulation of cell genesis in the hippo-
campal subregions of rats. Brain Res 1382: 147-154, 2011.
146. Huang T, Fang F, Chen L, Zhu Y, Zhang J, Chen X and Yan SS: 
Ginsenoside Rg1 attenuates oligomeric Aβ1-42-induced mito-
chondrial dysfunction. Curr Alzheimer Res 9: 388-395, 2012.
147. Zhang JT, Liu Y, Qu ZW, Zhang XL and Xiao HL: [Influence 
of ginsenoside Rb1 and Rg1 on some central neurotransmitter 
receptors and protein biosynthesis in the mouse brain]. Yao Xue 
Xue Bao 23: 12-16, 1988 (In Chinese).
148. Ying Y, Zhang JT, Shi CZ, Qu ZW and Liu Y: [Study on the 
nootropic mechanism of ginsenoside Rb1 and Rg1‑‑influence 
on mouse brain development]. Acta pharmaceutica Sinica 29: 
241-245, 1994 (In Chinese).
149. Zeng XS, Zhou XS, Luo FC, Jia JJ, Qi L, Yang ZX, Zhang W 
and Bai J: Comparative analysis of the neuroprotective effects 
of ginsenosides Rg1 and Rb1 extracted from Panax notoginseng 
against cerebral ischemia. Can J Physiol Pharmacol 92: 102-108, 
2014.
150. Huang XP, Ding H, Lu JD, Tang YH, Deng BX and Deng CQ: 
Effects of the combination of the main active components of 
Astragalus and Panax notoginseng on inflammation and 
apoptosis of nerve cell after cerebral ischemia-reperfusion. Am 
J Chin Med 43: 1419-1438, 2015.
151. Wang X, Zeng C, Lin J, Chen T, Zhao T, Jia Z, Xie X, Qiu Y, 
Su M, Jiang T, et al: Metabonomics approach to assessing 
the modulatory effects of St John’s wort, ginsenosides, and 
clomipramine in experimental depression. J Proteome Res 11: 
6223-6230, 2012.
152. Yamada N, Araki H and Yoshimura H: Identification of 
antidepressant-like ingredients in ginseng root (Panax ginseng 
C.A. Meyer) using a menopausal depressive-like state in female 
mice: Participation of 5-HT2A receptors. Psychopharmacology (Berl) 216: 589-599, 2011.
153. Kang A, Hao H, Zheng X, Liang Y, Xie Y, Xie T, Dai C, Zhao Q, 
Wu X, Xie L and Wang G: Peripheral anti‑inflammatory effects 
explain the ginsenosides paradox between poor brain distri-
bution and anti‑depression efficacy. J Neuroinflammation 8: 
100, 2011.
154. Zhang H, Li Z, Zhou Z, Yang H, Zhong Z and Lou C: 
Antidepressant-like effects of ginsenosides: A comparison of 
ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair. Pharmacol Biochem Behav 140: 17-26, 2016.
155. You Z, Yao Q, Shen J, Gu Z, Xu H, Wu Z, Chen C and Li L: 
Antidepressant-like effects of ginsenoside Rg3 in mice via 
activation of the hippocampal BDNF signaling cascade. J Nat 
Med 71: 367-379, 2017.
156. Liu X-Y, Zhou X-Y, Hou J-C, Zhu H, Wang Z, Liu JX and 
Zheng YQ: Ginsenoside Rd promotes neurogenesis in rat brain 
after transient focal cerebral ischemia via activation of PI3K/Akt 
pathway. Acta Pharmacol Sin 36: 421-428, 2015.
157. Xie Z, Shi M, Zhang C, Zhao H, Hui H and Zhao G: Ginsenoside 
Rd protects against cerebral ischemia-reperfusion injury via 
decreasing the expression of the NMDA receptor 2B subunit 
and its phosphorylated product. Neurochem Res 41: 2149-2159, 
2016.
158. Chen LM, Zhou XM, Cao YL and Hu WX: Neuroprotection of 
ginsenoside Re in cerebral ischemia-reperfusion injury in rats. J 
Asian Nat Prod Res 10: 439-445, 2008.
159. He B, Chen P, Yang J, Yun Y, Zhang X, Yang R and Shen Z: 
Neuroprotective effect of 20(R)-ginsenoside Rg(3) against 
transient focal cerebral ischemia in rats. Neurosci Lett 526: 
106-111, 2012.
160. Jiang B, Xiong Z, Yang J, Wang W, Wang Y, Hu ZL, Wang F and 
Chen JG: Antidepressant-like effects of ginsenoside Rg1 are due 
to activation of the BDNF signalling pathway and neurogenesis 
in the hippocampus. Br J Pharmacol 166: 1872-1887, 2012.
161. Liu Z, Qi Y, Cheng Z, Zhu X, Fan C and Yu SY: The effects 
of ginsenoside Rg1 on chronic stress induced depression-like 
behaviors, BDNF expression and the phosphorylation of PKA 
and CREB in rats. Neuroscience 322: 358-369, 2016.
162. Cui J, Jiang L and Xiang H: Ginsenoside Rb3 exerts 
antidepressant-like effects in several animal models. J 
Psychopharmacol 26: 697-713, 2012.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International (CC BY-NC-ND 4.0) License.
